PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 28400509-7 2017 The inhibition of FASN by cerulenin, a small molecule antibiotic, blocked cellular proliferation of KRAS-associated lung cancer cells. Cerulenin 26-35 fatty acid synthase Homo sapiens 18-22 28400509-7 2017 The inhibition of FASN by cerulenin, a small molecule antibiotic, blocked cellular proliferation of KRAS-associated lung cancer cells. Cerulenin 26-35 KRAS proto-oncogene, GTPase Homo sapiens 100-104 27713913-6 2016 Pharmacological inhibition of FASN activity with the mycotoxin cerulenin or the small compound C75 reversed CCN1-induced acquisition of estrogen independence and resistance to hormone therapies such as tamoxifen and fulvestrant in anchorage-independent growth assays. Cerulenin 63-72 fatty acid synthase Homo sapiens 30-34 28260110-13 2017 The combined treatment of emodin and cerulenin, a commercial FASN inhibitor, had an additive effect on these activities. Cerulenin 37-46 fatty acid synthase Homo sapiens 61-65 27918556-5 2017 The effects of FASN inhibitors cerulenin and orlistat on the proliferation, apoptosis, and migration of human lymphatic endothelial cells (HDLEC) were evaluated with in vitro models. Cerulenin 31-40 fatty acid synthase Homo sapiens 15-19 27918556-12 2017 Orlistat and cerulenin reduced VEGF-C secretion and, increase production of VEGF-D by B16-F10 and SK-Mel-25 melanoma cells. Cerulenin 13-22 vascular endothelial growth factor C Mus musculus 31-37 27918556-12 2017 Orlistat and cerulenin reduced VEGF-C secretion and, increase production of VEGF-D by B16-F10 and SK-Mel-25 melanoma cells. Cerulenin 13-22 vascular endothelial growth factor D Mus musculus 76-82 27765901-4 2016 We next investigated whether the inhibition of FASN by using a specific FASN inhibitor, cerulenin, can influence growth and EMT/metastatic potential of A549CisR and H157CisR cells. Cerulenin 88-97 fatty acid synthase Homo sapiens 47-51 27765901-4 2016 We next investigated whether the inhibition of FASN by using a specific FASN inhibitor, cerulenin, can influence growth and EMT/metastatic potential of A549CisR and H157CisR cells. Cerulenin 88-97 fatty acid synthase Homo sapiens 72-76 27713913-6 2016 Pharmacological inhibition of FASN activity with the mycotoxin cerulenin or the small compound C75 reversed CCN1-induced acquisition of estrogen independence and resistance to hormone therapies such as tamoxifen and fulvestrant in anchorage-independent growth assays. Cerulenin 63-72 cellular communication network factor 1 Homo sapiens 108-112 26936618-10 2016 Inhibition of FASN by cerulenin impaired glycolysis and migration in SK-BR-3 cells. Cerulenin 22-31 fatty acid synthase Homo sapiens 14-18 26967395-0 2016 Dephosphorylation and mitochondrial translocation of cofilin sensitizes human leukemia cells to cerulenin-induced apoptosis via the ROCK1/Akt/JNK signaling pathway. Cerulenin 96-105 cofilin 1 Homo sapiens 53-60 26967395-0 2016 Dephosphorylation and mitochondrial translocation of cofilin sensitizes human leukemia cells to cerulenin-induced apoptosis via the ROCK1/Akt/JNK signaling pathway. Cerulenin 96-105 Rho associated coiled-coil containing protein kinase 1 Homo sapiens 132-137 26967395-0 2016 Dephosphorylation and mitochondrial translocation of cofilin sensitizes human leukemia cells to cerulenin-induced apoptosis via the ROCK1/Akt/JNK signaling pathway. Cerulenin 96-105 AKT serine/threonine kinase 1 Homo sapiens 138-141 26967395-0 2016 Dephosphorylation and mitochondrial translocation of cofilin sensitizes human leukemia cells to cerulenin-induced apoptosis via the ROCK1/Akt/JNK signaling pathway. Cerulenin 96-105 mitogen-activated protein kinase 8 Homo sapiens 142-145 26967395-1 2016 In this study, we determined that cerulenin, a natural product inhibitor of fatty acid synthase, induces mitochondrial injury and apoptosis in human leukemia cells through the mitochondrial translocation of cofilin. Cerulenin 34-43 cofilin 1 Homo sapiens 207-214 26967395-2 2016 Only dephosphorylated cofilin could translocate to mitochondria during cerulenin-induced apoptosis. Cerulenin 71-80 cofilin 1 Homo sapiens 22-29 26967395-3 2016 Disruption of the ROCK1/Akt/JNK signaling pathway plays a critical role in the cerulenin-mediated dephosphorylation and mitochondrial translocation of cofilin and apoptosis. Cerulenin 79-88 Rho associated coiled-coil containing protein kinase 1 Homo sapiens 18-23 26967395-3 2016 Disruption of the ROCK1/Akt/JNK signaling pathway plays a critical role in the cerulenin-mediated dephosphorylation and mitochondrial translocation of cofilin and apoptosis. Cerulenin 79-88 AKT serine/threonine kinase 1 Homo sapiens 24-27 26967395-3 2016 Disruption of the ROCK1/Akt/JNK signaling pathway plays a critical role in the cerulenin-mediated dephosphorylation and mitochondrial translocation of cofilin and apoptosis. Cerulenin 79-88 mitogen-activated protein kinase 8 Homo sapiens 28-31 26967395-3 2016 Disruption of the ROCK1/Akt/JNK signaling pathway plays a critical role in the cerulenin-mediated dephosphorylation and mitochondrial translocation of cofilin and apoptosis. Cerulenin 79-88 cofilin 1 Homo sapiens 151-158 26967395-4 2016 In vivo studies demonstrated that cerulenin-mediated inhibition of tumor growth in a mouse xenograft model of leukemia was associated with mitochondrial translocation of cofilin and apoptosis. Cerulenin 34-43 cofilin 1 Homo sapiens 170-177 26967395-5 2016 These data are consistent with a hierarchical model in which induction of apoptosis by cerulenin primarily results from activation of ROCK1, inactivation of Akt, and activation of JNK. Cerulenin 87-96 Rho associated coiled-coil containing protein kinase 1 Homo sapiens 134-139 26967395-5 2016 These data are consistent with a hierarchical model in which induction of apoptosis by cerulenin primarily results from activation of ROCK1, inactivation of Akt, and activation of JNK. Cerulenin 87-96 AKT serine/threonine kinase 1 Homo sapiens 157-160 26967395-5 2016 These data are consistent with a hierarchical model in which induction of apoptosis by cerulenin primarily results from activation of ROCK1, inactivation of Akt, and activation of JNK. Cerulenin 87-96 mitogen-activated protein kinase 8 Homo sapiens 180-183 26967395-7 2016 Our study has revealed a novel role of cofilin in the regulation of mitochondrial injury and apoptosis and suggests that cerulenin is a potential drug for the treatment of leukemia. Cerulenin 121-130 cofilin 1 Homo sapiens 39-46 26109148-4 2016 METHODS: Cerulenin was used to suppress the FASN expression in human colorectal cancer cell lines (HT29 and LoVo). Cerulenin 9-18 fatty acid synthase Homo sapiens 44-48 26808816-6 2016 When GSCs were treated with 20 muM cerulenin, a pharmacological inhibitor of FASN, their proliferation and migration were significantly suppressed and de novo lipogenesis decreased. Cerulenin 35-44 fatty acid synthase Homo sapiens 77-81 26808816-7 2016 Furthermore, following cerulenin treatment, expression of the GSC markers nestin, Sox2 and fatty acid binding protein (FABP7), markers of GCSs, decreased while that of glial fibrillary acidic protein (GFAP) expression increased. Cerulenin 23-32 SRY-box transcription factor 2 Homo sapiens 82-86 26808816-7 2016 Furthermore, following cerulenin treatment, expression of the GSC markers nestin, Sox2 and fatty acid binding protein (FABP7), markers of GCSs, decreased while that of glial fibrillary acidic protein (GFAP) expression increased. Cerulenin 23-32 glutamic-oxaloacetic transaminase 2 Homo sapiens 91-117 26808816-7 2016 Furthermore, following cerulenin treatment, expression of the GSC markers nestin, Sox2 and fatty acid binding protein (FABP7), markers of GCSs, decreased while that of glial fibrillary acidic protein (GFAP) expression increased. Cerulenin 23-32 fatty acid binding protein 7 Homo sapiens 119-124 26808816-7 2016 Furthermore, following cerulenin treatment, expression of the GSC markers nestin, Sox2 and fatty acid binding protein (FABP7), markers of GCSs, decreased while that of glial fibrillary acidic protein (GFAP) expression increased. Cerulenin 23-32 glial fibrillary acidic protein Homo sapiens 168-199 26808816-7 2016 Furthermore, following cerulenin treatment, expression of the GSC markers nestin, Sox2 and fatty acid binding protein (FABP7), markers of GCSs, decreased while that of glial fibrillary acidic protein (GFAP) expression increased. Cerulenin 23-32 glial fibrillary acidic protein Homo sapiens 201-205 25825864-8 2015 Mammalian target of rapamycin (mTOR) was phosphorylated by hypoxia, whereas inhibition of FASN by cerulenin suppressed hypoxia-induced mTOR phosphorylation as well as UCB-hMSC proliferation and migration. Cerulenin 98-107 fatty acid synthase Homo sapiens 90-94 26484401-3 2015 Inhibitors of fatty acid synthase, such as the cerulenin synthetic analog C75, decrease prostate cancer cell proliferation, increase apoptosis and decrease tumor growth in experimental models. Cerulenin 47-56 fatty acid synthase Homo sapiens 14-33 25825864-8 2015 Mammalian target of rapamycin (mTOR) was phosphorylated by hypoxia, whereas inhibition of FASN by cerulenin suppressed hypoxia-induced mTOR phosphorylation as well as UCB-hMSC proliferation and migration. Cerulenin 98-107 mechanistic target of rapamycin kinase Homo sapiens 135-139 25947066-6 2015 In most samples, the FASN inhibitor cerulenin markedly decreased FASN expression and cell viability and induced apoptosis. Cerulenin 36-45 fatty acid synthase Homo sapiens 21-25 25947066-6 2015 In most samples, the FASN inhibitor cerulenin markedly decreased FASN expression and cell viability and induced apoptosis. Cerulenin 36-45 fatty acid synthase Homo sapiens 65-69 25574840-9 2015 FASN inhibition by shRNA and treatment with the chemical inhibitors C75 and cerulenin suppressed NLRP3-mediated caspase-1 activation and inhibited NLRP3 and pro-IL-1beta gene expression in macrophages. Cerulenin 76-85 fatty acid synthase Mus musculus 0-4 25574840-9 2015 FASN inhibition by shRNA and treatment with the chemical inhibitors C75 and cerulenin suppressed NLRP3-mediated caspase-1 activation and inhibited NLRP3 and pro-IL-1beta gene expression in macrophages. Cerulenin 76-85 NLR family, pyrin domain containing 3 Mus musculus 97-102 25574840-9 2015 FASN inhibition by shRNA and treatment with the chemical inhibitors C75 and cerulenin suppressed NLRP3-mediated caspase-1 activation and inhibited NLRP3 and pro-IL-1beta gene expression in macrophages. Cerulenin 76-85 caspase 1 Mus musculus 112-121 25574840-9 2015 FASN inhibition by shRNA and treatment with the chemical inhibitors C75 and cerulenin suppressed NLRP3-mediated caspase-1 activation and inhibited NLRP3 and pro-IL-1beta gene expression in macrophages. Cerulenin 76-85 NLR family, pyrin domain containing 3 Mus musculus 147-152 25574840-9 2015 FASN inhibition by shRNA and treatment with the chemical inhibitors C75 and cerulenin suppressed NLRP3-mediated caspase-1 activation and inhibited NLRP3 and pro-IL-1beta gene expression in macrophages. Cerulenin 76-85 interleukin 1 beta Mus musculus 161-169 24866893-6 2014 Cerulenin, a FASN inhibitor, synergized with rapamycin to induce apoptosis and inhibit cell migration and tumorigenesis in ER/HER2-positive breast cancer cells. Cerulenin 0-9 fatty acid synthase Homo sapiens 13-17 25787154-6 2015 We also isolated a spontaneous cerulenin-resistant sake yeast FAS2-G1250S mutant, G9CR, which showed both high ethyl caproate-producing ability and integrity/intactness of the checkpoint mechanisms. Cerulenin 31-40 trifunctional fatty acid synthase subunit FAS2 Saccharomyces cerevisiae S288C 62-66 24964211-4 2014 We previously reported that two FASN inhibitors, cerulenin and orlistat, induce apoptosis in B16-F10 mouse melanoma cells via the intrinsic apoptosis pathway. Cerulenin 49-58 fatty acid synthase Mus musculus 32-36 24964211-6 2014 Cerulenin and orlistat treatments were found to induce apoptosis and decrease cell proliferation, in addition to inducing the release of mitochondrial cytochrome c and activating caspases-9 and -3. Cerulenin 0-9 caspase 9 Mus musculus 179-196 24866893-6 2014 Cerulenin, a FASN inhibitor, synergized with rapamycin to induce apoptosis and inhibit cell migration and tumorigenesis in ER/HER2-positive breast cancer cells. Cerulenin 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 126-130 24520215-7 2014 Cerulenin inhibited MCF-7-MEK5 cell migration and EMT, and reduced FASN expression and down-stream proteins L-FABP, VEGF, and VEGFR-2. Cerulenin 0-9 vascular endothelial growth factor A Homo sapiens 116-120 24520215-7 2014 Cerulenin inhibited MCF-7-MEK5 cell migration and EMT, and reduced FASN expression and down-stream proteins L-FABP, VEGF, and VEGFR-2. Cerulenin 0-9 kinase insert domain receptor Homo sapiens 126-133 24520215-8 2014 MCF-7-MEK5 cells showed higher sensitivity to Cerulenin than MCF-7 cells. Cerulenin 46-55 mitogen-activated protein kinase kinase 5 Homo sapiens 6-10 24520215-10 2014 Immunohistochemistry further showed that increased percentage of FASN-positive cells in the tumor tissue was associated with increased percentages of L-FABP- and VEGF-positive cells and the Cerulenin treatment could reverse the effect. Cerulenin 190-199 fatty acid synthase Homo sapiens 65-69 24520215-10 2014 Immunohistochemistry further showed that increased percentage of FASN-positive cells in the tumor tissue was associated with increased percentages of L-FABP- and VEGF-positive cells and the Cerulenin treatment could reverse the effect. Cerulenin 190-199 fatty acid binding protein 1 Homo sapiens 150-156 24520215-10 2014 Immunohistochemistry further showed that increased percentage of FASN-positive cells in the tumor tissue was associated with increased percentages of L-FABP- and VEGF-positive cells and the Cerulenin treatment could reverse the effect. Cerulenin 190-199 vascular endothelial growth factor A Homo sapiens 162-166 23827961-7 2013 injection of cerulenin, a natural FAS inhibitor, increased the core body and IBAT temperatures. Cerulenin 13-22 fatty acid synthase Rattus norvegicus 34-37 24520215-7 2014 Cerulenin inhibited MCF-7-MEK5 cell migration and EMT, and reduced FASN expression and down-stream proteins L-FABP, VEGF, and VEGFR-2. Cerulenin 0-9 mitogen-activated protein kinase kinase 5 Homo sapiens 26-30 24520215-7 2014 Cerulenin inhibited MCF-7-MEK5 cell migration and EMT, and reduced FASN expression and down-stream proteins L-FABP, VEGF, and VEGFR-2. Cerulenin 0-9 fatty acid synthase Homo sapiens 67-71 24520215-7 2014 Cerulenin inhibited MCF-7-MEK5 cell migration and EMT, and reduced FASN expression and down-stream proteins L-FABP, VEGF, and VEGFR-2. Cerulenin 0-9 fatty acid binding protein 1 Homo sapiens 108-114 25292037-3 2014 Tumour cells were implanted into nude mice for in vivo analysis, and cerulenin was used as a FASN inhibitor. Cerulenin 69-78 fatty acid synthase Mus musculus 93-97 25292037-6 2014 The expression of Wnt-1 and beta-catenin in MCF-7-MEK5 decreased after cerulenin treatment, whereas cytC expression increased. Cerulenin 71-80 Wnt family member 1 Homo sapiens 18-23 25292037-6 2014 The expression of Wnt-1 and beta-catenin in MCF-7-MEK5 decreased after cerulenin treatment, whereas cytC expression increased. Cerulenin 71-80 catenin beta 1 Homo sapiens 28-40 25292037-6 2014 The expression of Wnt-1 and beta-catenin in MCF-7-MEK5 decreased after cerulenin treatment, whereas cytC expression increased. Cerulenin 71-80 mitogen-activated protein kinase kinase 5 Homo sapiens 50-54 24046423-4 2013 Cerulenin administration significantly (P < 0.05) decreased food intake and induced Hsp-70 mRNA levels in muscle, but not in liver or hypothalamus of 2-wk-old broiler chickens. Cerulenin 0-9 heat shock protein family A (Hsp70) member 2 Gallus gallus 87-93 23970552-7 2013 In the presence of cerulenin, an inhibitor of de novo fatty acid synthesis, the dgk1Delta mutant expressing DGK1(reb1) exhibited a significant defect in growth as well as in the synthesis of phospholipids from triacylglycerol mobilization. Cerulenin 19-28 diacylglycerol kinase Saccharomyces cerevisiae S288C 108-112 23970552-7 2013 In the presence of cerulenin, an inhibitor of de novo fatty acid synthesis, the dgk1Delta mutant expressing DGK1(reb1) exhibited a significant defect in growth as well as in the synthesis of phospholipids from triacylglycerol mobilization. Cerulenin 19-28 DNA-binding protein REB1 Saccharomyces cerevisiae S288C 113-117 24046423-7 2013 In attempt to discriminate between the effect of cerulenin and cerulenin-reduced food intake on Hsp-70 gene expression, we also evaluated the effect of food deprivation on the same cellular responses. Cerulenin 63-72 heat shock protein family A (Hsp70) member 2 Gallus gallus 96-102 24086674-0 2013 Cerulenin blockade of fatty acid synthase reverses hepatic steatosis in ob/ob mice. Cerulenin 0-9 fatty acid synthase Mus musculus 22-41 24086674-2 2013 The objective of this study was to investigate the effect of the fatty acid synthase inhibitor cerulenin on hepatic function in steatotic ob/ob mice. Cerulenin 95-104 fatty acid synthase Mus musculus 65-84 24086674-7 2013 Expression of peroxisome proliferator-activated receptors alpha and gamma and uncoupling protein 2 were suppressed with cerulenin treatment and paralleled changes in AST/ALT levels. Cerulenin 120-129 glutamic pyruvic transaminase, soluble Mus musculus 170-173 23816424-5 2013 FASN inhibitors (cerulenin, triclosan and orlistat) significantly inhibited FASN enzyme activity (P<0.05) in Y79 RB cells. Cerulenin 17-26 fatty acid synthase Homo sapiens 0-4 23816424-5 2013 FASN inhibitors (cerulenin, triclosan and orlistat) significantly inhibited FASN enzyme activity (P<0.05) in Y79 RB cells. Cerulenin 17-26 fatty acid synthase Homo sapiens 76-80 23108760-0 2013 Fatty acid synthase inhibitor cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin 30-39 fatty acid synthase Homo sapiens 0-19 24046423-0 2013 Cerulenin upregulates heat shock protein-70 gene expression in chicken muscle. Cerulenin 0-9 heat shock protein family A (Hsp70) member 2 Gallus gallus 22-43 24046423-2 2013 Because cerulenin, the natural antibiotic product of the fungus Cephalosporium ceruleans and a broad-spectrum fatty acid synthesis (FAS) inhibitor, has been shown to affect food intake and energy balance, and because the biomarker of stress Hsp-70 gene was found to interact directly with fatty acids, we hypothesized that cerulenin may regulate Hsp-70 gene expression. Cerulenin 8-17 heat shock protein family A (Hsp70) member 2 Gallus gallus 241-247 24046423-2 2013 Because cerulenin, the natural antibiotic product of the fungus Cephalosporium ceruleans and a broad-spectrum fatty acid synthesis (FAS) inhibitor, has been shown to affect food intake and energy balance, and because the biomarker of stress Hsp-70 gene was found to interact directly with fatty acids, we hypothesized that cerulenin may regulate Hsp-70 gene expression. Cerulenin 8-17 heat shock protein family A (Hsp70) member 2 Gallus gallus 346-352 23754252-2 2013 Cerulenin, a natural inhibitor of fatty acid synthase, induced apoptosis in the human colon cancer cell lines HCT116 and RKO. Cerulenin 0-9 fatty acid synthase Homo sapiens 34-53 23754252-4 2013 Cerulenin treatment was associated with reduced levels of phosphorylated Akt, activation of p38 and induced caspase-3 cleavage and finally caused apoptosis. Cerulenin 0-9 AKT serine/threonine kinase 1 Homo sapiens 73-76 23754252-4 2013 Cerulenin treatment was associated with reduced levels of phosphorylated Akt, activation of p38 and induced caspase-3 cleavage and finally caused apoptosis. Cerulenin 0-9 mitogen-activated protein kinase 14 Homo sapiens 92-95 23754252-4 2013 Cerulenin treatment was associated with reduced levels of phosphorylated Akt, activation of p38 and induced caspase-3 cleavage and finally caused apoptosis. Cerulenin 0-9 caspase 3 Homo sapiens 108-117 23754252-6 2013 In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin. Cerulenin 20-29 tumor protein p53 Homo sapiens 65-68 23754252-6 2013 In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin. Cerulenin 20-29 H3 histone pseudogene 16 Homo sapiens 69-72 23754252-6 2013 In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin. Cerulenin 20-29 mitogen-activated protein kinase 14 Homo sapiens 85-88 23754252-6 2013 In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin. Cerulenin 20-29 caspase 3 Homo sapiens 145-154 23754252-6 2013 In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin. Cerulenin 194-203 tumor protein p53 Homo sapiens 65-68 23754252-6 2013 In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin. Cerulenin 194-203 H3 histone pseudogene 16 Homo sapiens 69-72 23754252-6 2013 In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin. Cerulenin 194-203 mitogen-activated protein kinase 14 Homo sapiens 85-88 23754252-6 2013 In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin. Cerulenin 194-203 caspase 3 Homo sapiens 145-154 23219804-9 2013 2-bromopalmitate and cerulenin, two known palmitoylation inhibitors, completely inhibited p55 palmitoylation, and protein palmitoyl thioesterase-1 (PPT1) reduced it, without affecting the association between lipid rafts and membrane-skeleton, indicating, on the one hand, that p55 palmitoylation is enzymatic, and, on the other, that it is not involved in the modulation of the linkage of lipid rafts to the membrane-skeleton. Cerulenin 21-30 MAGUK p55 scaffold protein 1 Homo sapiens 90-93 23219804-9 2013 2-bromopalmitate and cerulenin, two known palmitoylation inhibitors, completely inhibited p55 palmitoylation, and protein palmitoyl thioesterase-1 (PPT1) reduced it, without affecting the association between lipid rafts and membrane-skeleton, indicating, on the one hand, that p55 palmitoylation is enzymatic, and, on the other, that it is not involved in the modulation of the linkage of lipid rafts to the membrane-skeleton. Cerulenin 21-30 MAGUK p55 scaffold protein 1 Homo sapiens 277-280 23108760-2 2013 One of the most widely used inhibitors of FASN, cerulenin, is a natural product of Cephalosporium caerulens. Cerulenin 48-57 fatty acid synthase Homo sapiens 42-46 23146134-7 2013 When integrated into the genome of a haploid wine strain, the mutated YAP1 alleles partially reproduced the low-VA production phenotype of the diploid cerulenin-resistant strains, suggesting that YAP1 might play a role in (regulating) acetic acid production during fermentation. Cerulenin 151-160 DNA-binding transcription factor YAP1 Saccharomyces cerevisiae S288C 70-74 23146134-7 2013 When integrated into the genome of a haploid wine strain, the mutated YAP1 alleles partially reproduced the low-VA production phenotype of the diploid cerulenin-resistant strains, suggesting that YAP1 might play a role in (regulating) acetic acid production during fermentation. Cerulenin 151-160 DNA-binding transcription factor YAP1 Saccharomyces cerevisiae S288C 196-200 22805178-2 2012 Here, it is shown that in the presence of cerulenin, a known inhibitor of the fatty acid synthase complex, biofilm formation is inhibited together with FLO11 transcription in a flor strain of Saccharomyces cerevisiae, while the administration of saturated fatty acids to cerulenin-containing medium restores biofilm formation and FLO11 transcription. Cerulenin 42-51 Flo11p Saccharomyces cerevisiae S288C 152-157 23441619-3 2013 Differential gene expression in cultured retinoblastoma cells induced by cerulenin, a chemical inhibitor of FASN, was evaluated by cDNA microarray analysis. Cerulenin 73-82 fatty acid synthase Homo sapiens 108-112 23441619-4 2013 Cerulenin treatment resulted in significant upregulation of cytochrome c (CYCS) by 1.2-fold, whereas S-phase kinase-associated protein-2 (SKP2), a negative regulator of cell cycle, and the lipid metabolic genes (PPARA, RXRA, and ACACB) were significantly downregulated by -1.59-, -1.8-, -1.83-, and -1.5-fold, respectively, in comparison with untreated cancer cells. Cerulenin 0-9 cytochrome c, somatic Homo sapiens 60-72 23441619-4 2013 Cerulenin treatment resulted in significant upregulation of cytochrome c (CYCS) by 1.2-fold, whereas S-phase kinase-associated protein-2 (SKP2), a negative regulator of cell cycle, and the lipid metabolic genes (PPARA, RXRA, and ACACB) were significantly downregulated by -1.59-, -1.8-, -1.83-, and -1.5-fold, respectively, in comparison with untreated cancer cells. Cerulenin 0-9 cytochrome c, somatic Homo sapiens 74-78 23441619-4 2013 Cerulenin treatment resulted in significant upregulation of cytochrome c (CYCS) by 1.2-fold, whereas S-phase kinase-associated protein-2 (SKP2), a negative regulator of cell cycle, and the lipid metabolic genes (PPARA, RXRA, and ACACB) were significantly downregulated by -1.59-, -1.8-, -1.83-, and -1.5-fold, respectively, in comparison with untreated cancer cells. Cerulenin 0-9 peroxisome proliferator activated receptor alpha Homo sapiens 212-217 23441619-4 2013 Cerulenin treatment resulted in significant upregulation of cytochrome c (CYCS) by 1.2-fold, whereas S-phase kinase-associated protein-2 (SKP2), a negative regulator of cell cycle, and the lipid metabolic genes (PPARA, RXRA, and ACACB) were significantly downregulated by -1.59-, -1.8-, -1.83-, and -1.5-fold, respectively, in comparison with untreated cancer cells. Cerulenin 0-9 retinoid X receptor alpha Homo sapiens 219-223 23441619-4 2013 Cerulenin treatment resulted in significant upregulation of cytochrome c (CYCS) by 1.2-fold, whereas S-phase kinase-associated protein-2 (SKP2), a negative regulator of cell cycle, and the lipid metabolic genes (PPARA, RXRA, and ACACB) were significantly downregulated by -1.59-, -1.8-, -1.83-, and -1.5-fold, respectively, in comparison with untreated cancer cells. Cerulenin 0-9 acetyl-CoA carboxylase beta Homo sapiens 229-234 23135268-6 2012 In addition, the proliferative effects induced by E2 and G-1 in these cells involved FASN as the inhibitor of its activity, named cerulenin, abolished the growth response to both ligands. Cerulenin 130-139 small nucleolar RNA, C/D box 12C Homo sapiens 50-60 23135268-6 2012 In addition, the proliferative effects induced by E2 and G-1 in these cells involved FASN as the inhibitor of its activity, named cerulenin, abolished the growth response to both ligands. Cerulenin 130-139 fatty acid synthase Homo sapiens 85-89 22805178-2 2012 Here, it is shown that in the presence of cerulenin, a known inhibitor of the fatty acid synthase complex, biofilm formation is inhibited together with FLO11 transcription in a flor strain of Saccharomyces cerevisiae, while the administration of saturated fatty acids to cerulenin-containing medium restores biofilm formation and FLO11 transcription. Cerulenin 42-51 Flo11p Saccharomyces cerevisiae S288C 330-335 22151915-3 2012 Here, three inhibitors targeting different domains of FASN--cerulenin, triclosan and orlistat--were evaluated for their anti-proliferative efficacy in ocular cancer, retinoblastoma (RB) cells and their toxicity (if any) in normal cells. Cerulenin 60-69 fatty acid synthase Mus musculus 54-58 22892389-9 2012 Cerulenin and orlistat stimulated the production of total VEGFA in B16-F10, SK-MEL-25, and SCC-9 cells. Cerulenin 0-9 vascular endothelial growth factor A Mus musculus 58-63 22151915-6 2012 The IC(50) after 48 and 96 hr of incubation with the three anti-FASN agents showed that cerulenin, triclosan and orlistat inhibited retinoblastoma cell proliferation in a dose- and time-dependent manner. Cerulenin 88-97 fatty acid synthase Mus musculus 64-68 22381626-4 2012 It also induced terminal stalk cell differentiation in a mutant strain that does not produce DIF-1 (dmtA-) and after the treatment of cells with DIF-1 synthesis inhibitor cerulenin (100 muM). Cerulenin 171-180 latexin Homo sapiens 186-189 22426850-0 2012 Cerulenin-induced apoptosis is mediated by disrupting the interaction between AIF and hexokinase II. Cerulenin 0-9 apoptosis inducing factor mitochondria associated 1 Homo sapiens 90-93 22426850-0 2012 Cerulenin-induced apoptosis is mediated by disrupting the interaction between AIF and hexokinase II. Cerulenin 0-9 hexokinase 2 Homo sapiens 98-111 22426850-8 2012 Additionally, we sought to elucidate whether inhibition of the PI3K/Akt pathway can potentiate the anticancer effect of cerulenin. Cerulenin 132-141 AKT serine/threonine kinase 1 Homo sapiens 80-83 22426850-9 2012 Here, we showed that cerulenin disrupts the physical association between HKII and AIF, leading to eventual cell death. Cerulenin 21-30 hexokinase 2 Homo sapiens 73-77 22426850-9 2012 Here, we showed that cerulenin disrupts the physical association between HKII and AIF, leading to eventual cell death. Cerulenin 21-30 apoptosis inducing factor mitochondria associated 1 Homo sapiens 94-97 22426850-10 2012 In addition, LY294002, a PI3K/Akt inhibitor, sensitized ZR-75-1 breast cancer cells to cerulenin-induced apoptosis. Cerulenin 99-108 AKT serine/threonine kinase 1 Homo sapiens 30-33 22426850-11 2012 Collectively, cerulenin induces apoptosis via disrupting the interaction between AIF and HKII and inhibition of PI3K sensitizes cells to cerulenin-induced apoptosis in ZR-75-1 cells. Cerulenin 26-35 apoptosis inducing factor mitochondria associated 1 Homo sapiens 93-96 22426850-11 2012 Collectively, cerulenin induces apoptosis via disrupting the interaction between AIF and HKII and inhibition of PI3K sensitizes cells to cerulenin-induced apoptosis in ZR-75-1 cells. Cerulenin 26-35 hexokinase 2 Homo sapiens 101-105 22771636-6 2012 We performed the cerulenin, an inhibitor of FASN, to inhibit FASN expression in U2-OS cells. Cerulenin 17-26 fatty acid synthase Homo sapiens 44-48 22771636-6 2012 We performed the cerulenin, an inhibitor of FASN, to inhibit FASN expression in U2-OS cells. Cerulenin 17-26 fatty acid synthase Homo sapiens 61-65 21389266-4 2011 In contrast to two agents, C75 and cerulenin, that are widely used as inhibitors of mammalian fatty acid synthase, platensimycin specifically inhibits fatty acid synthesis but not sterol synthesis in rat primary hepatocytes. Cerulenin 35-44 fatty acid synthase Homo sapiens 94-113 21643005-13 2011 Treatment of LM-MCF-7 cells with the FASN inhibitor cerulenin (10 mumol/L) reduced all the levels of p-ERK1/2, 5-LOX, and LTB4. Cerulenin 52-61 fatty acid synthase Homo sapiens 37-41 21643005-13 2011 Treatment of LM-MCF-7 cells with the FASN inhibitor cerulenin (10 mumol/L) reduced all the levels of p-ERK1/2, 5-LOX, and LTB4. Cerulenin 52-61 mitogen-activated protein kinase 3 Homo sapiens 103-109 21643005-13 2011 Treatment of LM-MCF-7 cells with the FASN inhibitor cerulenin (10 mumol/L) reduced all the levels of p-ERK1/2, 5-LOX, and LTB4. Cerulenin 52-61 arachidonate 5-lipoxygenase Homo sapiens 111-116 21170507-8 2011 The IC50 for the combined rosiglitazone and FASN blockers contrasts with the relatively higher IC50 for rosiglitazone (45 +- 2 muM), the TZD drug troglitazone (13 +- 2 muM), cerulenin (32 +- 1 muM), or C75 (26 +- 3 muM) when these drugs were used alone. Cerulenin 174-183 fatty acid synthase Homo sapiens 44-48 20973802-3 2010 However, the clinical use of FASN inhibitors, such as cerulenin, C75, and epigallocatechin 3-gallate (EGCG), is limited by anorexia and induced body weight loss or by its low in vivo potency and stability. Cerulenin 54-63 fatty acid synthase Homo sapiens 29-33 20708434-2 2010 The FAS2 mutation FAS2-1250S of Saccharomyces cerevisiae generates a cerulenin-resistant phenotype. Cerulenin 69-78 trifunctional fatty acid synthase subunit FAS2 Saccharomyces cerevisiae S288C 4-8 20708434-2 2010 The FAS2 mutation FAS2-1250S of Saccharomyces cerevisiae generates a cerulenin-resistant phenotype. Cerulenin 69-78 trifunctional fatty acid synthase subunit FAS2 Saccharomyces cerevisiae S288C 18-22 23181152-2 2010 The ocular cancer, retinoblastoma cells were treated with fatty acid synthase (FASN) enzyme inhibitors: cerulenin, triclosan and orlistat. Cerulenin 104-113 fatty acid synthase Homo sapiens 58-77 23181152-2 2010 The ocular cancer, retinoblastoma cells were treated with fatty acid synthase (FASN) enzyme inhibitors: cerulenin, triclosan and orlistat. Cerulenin 104-113 fatty acid synthase Homo sapiens 79-83 23181152-5 2010 The crystal structures of ketoacyl synthase (PDB ID:3HHD) (cerulenin) and thioesterase (PDB ID:2PX6) (orlistat) domains of human FASN were utilized for docking, while for the non-crystallised human FASN enoyl reductase domain (triclosan), homology model was built and used for docking. Cerulenin 59-68 fatty acid synthase Homo sapiens 129-133 20728534-7 2010 The antioxidants N-acetyl-l-cysteine and Tiron, as well as the FAS inhibitor cerulenin, reversed the effects of CBR1 knockdown. Cerulenin 77-86 carbonyl reductase 1 Mus musculus 112-116 20805790-5 2011 Both FASN inhibitors, cerulenin and orlistat, significantly reduced melanoma cell proliferation and activated the intrinsic pathway of apoptosis, as demonstrated by the cytochrome c release and caspase-9 and -3 activation. Cerulenin 22-31 fatty acid synthase Mus musculus 5-9 20805790-5 2011 Both FASN inhibitors, cerulenin and orlistat, significantly reduced melanoma cell proliferation and activated the intrinsic pathway of apoptosis, as demonstrated by the cytochrome c release and caspase-9 and -3 activation. Cerulenin 22-31 caspase 9 Mus musculus 194-210 20491775-0 2010 Fatty acid synthase inhibitor cerulenin suppresses liver metastasis of colon cancer in mice. Cerulenin 30-39 fatty acid synthase Mus musculus 0-19 20491775-3 2010 Cerulenin, a natural inhibitor of FAS, induced apoptosis in these cell lines. Cerulenin 0-9 fatty acid synthase Mus musculus 34-37 20491775-6 2010 Cerulenin treatment was associated with reduced levels of phosphorylated Akt in Colon 26 cells, suggesting that inhibition of this signal transduction pathway might be involved in the chemopreventive activity of this compound. Cerulenin 0-9 thymoma viral proto-oncogene 1 Mus musculus 73-76 20511185-5 2010 Second, we demonstrated that treatment with the FAS inhibitor, cerulenin (Cer), significantly decreased meningioma cell survival in vitro. Cerulenin 63-72 fatty acid synthase Homo sapiens 48-51 20511185-5 2010 Second, we demonstrated that treatment with the FAS inhibitor, cerulenin (Cer), significantly decreased meningioma cell survival in vitro. Cerulenin 74-77 fatty acid synthase Homo sapiens 48-51 20126469-10 2010 Interestingly, we found that FAS was able to upregulate the expression of 5-LOX in a feedback manner by using cerulenin (an inhibitor of FAS). Cerulenin 110-119 fatty acid synthase Homo sapiens 29-32 20373869-3 2010 Early small-molecule FASN inhibitors such as cerulenin, C75 and orlistat have been shown to induce apoptosis in several cancer cell lines and to induce tumor growth delay in several cancer xenograft models but their mechanism is still not well understood. Cerulenin 45-54 fatty acid synthase Homo sapiens 21-25 20173757-7 2010 In function, flow cytometry analysis revealed that FAS contributed to the growth of hepatoma cells that was mediated by HBxDelta127, using cerulenin (a FAS inhibitor). Cerulenin 139-148 fatty acid synthase Homo sapiens 51-54 20173757-7 2010 In function, flow cytometry analysis revealed that FAS contributed to the growth of hepatoma cells that was mediated by HBxDelta127, using cerulenin (a FAS inhibitor). Cerulenin 139-148 fatty acid synthase Homo sapiens 152-155 19786337-9 2010 In contrast, cerulenin increased (P<0.01) visfatin gene expression in the liver and in muscle, but not in the hypothalamus. Cerulenin 13-22 nicotinamide phosphoribosyltransferase pseudogene 1 Gallus gallus 45-53 20372807-4 2010 The FASN inhibitors cerulenin and orlistat reduced the growth of two LS cell lines (LiSa2, SW872), as did inhibition of ACC with soraphen A. Cerulenin 20-29 fatty acid synthase Homo sapiens 4-8 20126469-10 2010 Interestingly, we found that FAS was able to upregulate the expression of 5-LOX in a feedback manner by using cerulenin (an inhibitor of FAS). Cerulenin 110-119 arachidonate 5-lipoxygenase Homo sapiens 74-79 20126469-10 2010 Interestingly, we found that FAS was able to upregulate the expression of 5-LOX in a feedback manner by using cerulenin (an inhibitor of FAS). Cerulenin 110-119 fatty acid synthase Homo sapiens 137-140 19959834-4 2010 Although cellular TAG hydrolysis is reduced in the tgl2 deletion mutant, overproduction of Tgl2p in this mutant leads to an increase in TAG degradation in the presence of fatty acid synthesis inhibitor cerulenin, but that of Tgl2p(S144A) does not. Cerulenin 202-211 triglyceride lipase Saccharomyces cerevisiae S288C 91-96 19253321-4 2009 The so obtained cerulenin derivatives were tested on multidrug-resistant Candida albicans isolates which constitutively overexpress either Mdr1 or Cdr1 and Cdr2. Cerulenin 16-25 ATP binding cassette subfamily B member 1 Homo sapiens 139-143 19932008-9 2010 In addition, each inhibitor for various lipid synthesis enzymes, such as TOFA (ACC inhibitor), cerulenin (FAS inhibitor) and trans-10, cis-12-CLA (SCD inhibitor), increased the MMP-1 expression significantly in a dose-dependent manner. Cerulenin 95-104 fatty acid synthase Homo sapiens 106-109 19932008-9 2010 In addition, each inhibitor for various lipid synthesis enzymes, such as TOFA (ACC inhibitor), cerulenin (FAS inhibitor) and trans-10, cis-12-CLA (SCD inhibitor), increased the MMP-1 expression significantly in a dose-dependent manner. Cerulenin 95-104 matrix metallopeptidase 1 Homo sapiens 177-182 19932008-10 2010 We also demonstrated that triolein could inhibit cerulenin-induced MMP-1 expression. Cerulenin 49-58 matrix metallopeptidase 1 Homo sapiens 67-72 19455666-6 2009 Since C75 also suppresses the activity of fatty acid synthase (FAS), we tested another FAS inhibitor, cerulenin. Cerulenin 102-111 fatty acid synthase Mus musculus 87-90 19253321-4 2009 The so obtained cerulenin derivatives were tested on multidrug-resistant Candida albicans isolates which constitutively overexpress either Mdr1 or Cdr1 and Cdr2. Cerulenin 16-25 cerebellar degeneration related protein 1 Homo sapiens 147-151 19253321-4 2009 The so obtained cerulenin derivatives were tested on multidrug-resistant Candida albicans isolates which constitutively overexpress either Mdr1 or Cdr1 and Cdr2. Cerulenin 16-25 cerebellar degeneration related protein 2 Homo sapiens 156-160 17904792-0 2007 Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells. Cerulenin 31-40 fatty acid synthase Homo sapiens 0-19 18776140-5 2008 RESEARCH DESIGN AND METHODS: We measured the hypothalamic phosphorylation of two downstream targets of mTORC1, S6 kinase 1 (S6K1) and S6 ribosomal protein (S6), after administration of the FAS inhibitors C75 and cerulenin in rats. Cerulenin 212-221 CREB regulated transcription coactivator 1 Mus musculus 103-109 18776140-5 2008 RESEARCH DESIGN AND METHODS: We measured the hypothalamic phosphorylation of two downstream targets of mTORC1, S6 kinase 1 (S6K1) and S6 ribosomal protein (S6), after administration of the FAS inhibitors C75 and cerulenin in rats. Cerulenin 212-221 ribosomal protein S6 kinase B1 Rattus norvegicus 111-122 18776140-8 2008 RESULTS: C75 and cerulenin increased phosphorylation of S6K1 and S6, and their anorexic action was reduced in rapamycin-treated rats and in S6K1(-/-) mice. Cerulenin 17-26 ribosomal protein S6 kinase B1 Rattus norvegicus 56-60 18776140-8 2008 RESULTS: C75 and cerulenin increased phosphorylation of S6K1 and S6, and their anorexic action was reduced in rapamycin-treated rats and in S6K1(-/-) mice. Cerulenin 17-26 ribosomal protein S6 kinase B1 Rattus norvegicus 140-144 18410446-1 2008 This study investigated the biological significance of the inhibition of fatty acid synthase (FAS) in multiple myeloma (MM) using the small molecule inhibitor Cerulenin. Cerulenin 159-168 fatty acid synthase Homo sapiens 73-92 18410446-1 2008 This study investigated the biological significance of the inhibition of fatty acid synthase (FAS) in multiple myeloma (MM) using the small molecule inhibitor Cerulenin. Cerulenin 159-168 fatty acid synthase Homo sapiens 94-97 18410446-2 2008 Cerulenin triggered growth inhibition in both MM cell lines and MM patient cells, and overcame the survival and growth advantages conferred by interleukin-6, insulin-like growth factor-1, and bone marrow stromal cells. Cerulenin 0-9 interleukin 6 Homo sapiens 143-156 18410446-2 2008 Cerulenin triggered growth inhibition in both MM cell lines and MM patient cells, and overcame the survival and growth advantages conferred by interleukin-6, insulin-like growth factor-1, and bone marrow stromal cells. Cerulenin 0-9 insulin like growth factor 1 Homo sapiens 158-186 18410446-4 2008 In addition, treatment of MM cells with Cerulenin primarily up-regulated apoptosis-inducing factor/endonuclease G, mediators of caspase-independent apoptosis. Cerulenin 40-49 endonuclease G Homo sapiens 99-113 18410446-5 2008 Importantly, Cerulenin induced endoplasmic reticulum stress response via up-regulation of the Grp78/IRE1alpha/JNK pathway. Cerulenin 13-22 heat shock protein family A (Hsp70) member 5 Homo sapiens 94-99 18410446-5 2008 Importantly, Cerulenin induced endoplasmic reticulum stress response via up-regulation of the Grp78/IRE1alpha/JNK pathway. Cerulenin 13-22 endoplasmic reticulum to nucleus signaling 1 Homo sapiens 100-109 18410446-5 2008 Importantly, Cerulenin induced endoplasmic reticulum stress response via up-regulation of the Grp78/IRE1alpha/JNK pathway. Cerulenin 13-22 mitogen-activated protein kinase 8 Homo sapiens 110-113 18410446-6 2008 Although the C-Jun-NH(2)-terminal kinase (JNK) inhibitor SP600215 blocked Cerulenin-induced cytotoxicity, it did not inhibit apoptosis and caspase cleavage. Cerulenin 74-83 mitogen-activated protein kinase 8 Homo sapiens 42-45 18410446-8 2008 Our results therefore indicate that inhibition of FAS by Cerulenin primarily triggered caspase-independent apoptosis and JNK-dependent cytotoxicity in MM cells. Cerulenin 57-66 fatty acid synthase Homo sapiens 50-53 18410446-8 2008 Our results therefore indicate that inhibition of FAS by Cerulenin primarily triggered caspase-independent apoptosis and JNK-dependent cytotoxicity in MM cells. Cerulenin 57-66 mitogen-activated protein kinase 8 Homo sapiens 121-124 18239060-8 2008 Increased FASN expression in IEC-6 cells by addition of liver X receptor agonist T0901317 did not affect apurinic/apyrimidinic site number, but enhanced cell killing by cerulenin, a FASN inhibitor. Cerulenin 169-178 fatty acid synthase Rattus norvegicus 10-14 18239060-8 2008 Increased FASN expression in IEC-6 cells by addition of liver X receptor agonist T0901317 did not affect apurinic/apyrimidinic site number, but enhanced cell killing by cerulenin, a FASN inhibitor. Cerulenin 169-178 fatty acid synthase Rattus norvegicus 182-186 18056987-7 2008 The FAS inhibitor cerulenin produced dose-dependent (560 nmol) hypophagia for 1 day, weight loss for 2 days, and weight regain to vehicle control by day 3. Cerulenin 18-27 fatty acid synthase Mus musculus 4-7 17975142-0 2007 Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation. Cerulenin 153-162 PRA1 domain family member 2 Homo sapiens 14-63 17975142-0 2007 Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation. Cerulenin 153-162 PRA1 domain family member 2 Homo sapiens 65-70 17975142-10 2007 PRAF2 localized in bright cytoplasmic punctae and protein levels increased in neuroblastoma cells that underwent cerulenin-induced apoptosis. Cerulenin 113-122 PRA1 domain family member 2 Homo sapiens 0-5 18723500-8 2008 The drop in PCho levels following FASN inhibition was confirmed in SKOV-3 ovarian cancer cells treated with Orlistat and in MCF-7 breast cancer cells treated with Orlistat as well as cerulenin. Cerulenin 183-192 fatty acid synthase Homo sapiens 34-38 18246124-5 2008 Fas inhibitors cerulenin or C75 inhibited 2-ME-induced caspase activation, PARP cleavage, apoptosis and reversed mitochondrial membrane hyperpolarization, thereby recapitulating the increased expression of MTS-hOGG1. Cerulenin 15-24 poly(ADP-ribose) polymerase 1 Homo sapiens 75-79 18246124-5 2008 Fas inhibitors cerulenin or C75 inhibited 2-ME-induced caspase activation, PARP cleavage, apoptosis and reversed mitochondrial membrane hyperpolarization, thereby recapitulating the increased expression of MTS-hOGG1. Cerulenin 15-24 8-oxoguanine DNA glycosylase Homo sapiens 210-215 18543396-9 2008 U266 cells treated with 20 microg/ml cerulenin for 12 and 24 h also showed early sign of apoptosis with 56.9% and 69.3% Annexin V(+)/PI(-) cells, and late apoptotic and necrotic cells with 3.2% and 17.6% Annexin V(+)/PI(+) cells. Cerulenin 37-46 annexin A5 Homo sapiens 120-129 18543396-9 2008 U266 cells treated with 20 microg/ml cerulenin for 12 and 24 h also showed early sign of apoptosis with 56.9% and 69.3% Annexin V(+)/PI(-) cells, and late apoptotic and necrotic cells with 3.2% and 17.6% Annexin V(+)/PI(+) cells. Cerulenin 37-46 annexin A5 Homo sapiens 204-213 18543396-11 2008 Cerulenin greatly inhibited metabolic activity/cell proliferation of U266 cells and induced apoptosis, suggesting that FAS is an effective target for pharmacological therapy in human multiple myeloma. Cerulenin 0-9 fatty acid synthase Homo sapiens 119-122 18259941-6 2008 Importantly, CDDO-Im produced a dose-dependent apoptotic effect in the LiSa-2 cell line, and simultaneous treatment with CDDO-Im and the fatty acid synthase inhibitor Cerulenin produced a synergistic cytotoxic effect. Cerulenin 167-176 fatty acid synthase Homo sapiens 137-156 17904792-3 2007 The growth-inhibitory effects of FAS inhibitors cerulenin and C75 were then investigated on these cancer cell lines, particularly the human melanoma A-375. Cerulenin 48-57 fatty acid synthase Homo sapiens 33-36 17904792-5 2007 Immunoblotting studies showed that both cerulenin and C75 induced poly(ADP-ribose) polymerase (PARP) cleavage in the melanoma cells dose-dependently. Cerulenin 40-49 poly(ADP-ribose) polymerase 1 Homo sapiens 66-93 17904792-5 2007 Immunoblotting studies showed that both cerulenin and C75 induced poly(ADP-ribose) polymerase (PARP) cleavage in the melanoma cells dose-dependently. Cerulenin 40-49 poly(ADP-ribose) polymerase 1 Homo sapiens 95-99 17877200-2 2007 METHODS: The expression changes of 96 apoptosis related genes were analyzed by superArray cDNA in U266 cells treated with cerulenin (20 microg/ml) for 12 h. Semi-quantitative RT-PCR was used to confirm the representative expression changes genes, Rip2, caspase 9 and TRAF2. Cerulenin 122-131 receptor interacting serine/threonine kinase 2 Homo sapiens 247-251 17786362-3 2007 Upon pharmacological inhibition of FASN activity using the natural antibiotic cerulenin [(2S,3R)-2,3-epoxy-4-oxo-7E,10E-dodecadienamide], we evaluated the role of FASN-catalyzed endogenous fatty acid biogenesis on the sensitivity of SK-Br3, MCF-7 and MDA-MB-231 breast cancer cell lines to the anti-metabolite 5-fluorouracil (5-FU). Cerulenin 78-87 fatty acid synthase Homo sapiens 35-39 17786362-3 2007 Upon pharmacological inhibition of FASN activity using the natural antibiotic cerulenin [(2S,3R)-2,3-epoxy-4-oxo-7E,10E-dodecadienamide], we evaluated the role of FASN-catalyzed endogenous fatty acid biogenesis on the sensitivity of SK-Br3, MCF-7 and MDA-MB-231 breast cancer cell lines to the anti-metabolite 5-fluorouracil (5-FU). Cerulenin 78-87 fatty acid synthase Homo sapiens 163-167 17786362-12 2007 Our current findings revealing a schedule-dependent synergistic interaction between 5-FU and cerulenin represents, to the best of our knowledge, the first evidence that FASN-catalyzed de novo FA biogenesis plays a key role in regulating breast cancer cell response to antimetabolite-based therapies. Cerulenin 93-102 fatty acid synthase Homo sapiens 169-173 17877200-2 2007 METHODS: The expression changes of 96 apoptosis related genes were analyzed by superArray cDNA in U266 cells treated with cerulenin (20 microg/ml) for 12 h. Semi-quantitative RT-PCR was used to confirm the representative expression changes genes, Rip2, caspase 9 and TRAF2. Cerulenin 122-131 caspase 9 Homo sapiens 253-262 17877200-2 2007 METHODS: The expression changes of 96 apoptosis related genes were analyzed by superArray cDNA in U266 cells treated with cerulenin (20 microg/ml) for 12 h. Semi-quantitative RT-PCR was used to confirm the representative expression changes genes, Rip2, caspase 9 and TRAF2. Cerulenin 122-131 TNF receptor associated factor 2 Homo sapiens 267-272 17877200-4 2007 The expression of caspase 9 was increased markedly, indicating that mitochondria pathway played a key role in cerulenin inducing apoptosis and TRAF2 expression change suggested that nuclear factor (NF) participates in cerulenin inducing apoptosis. Cerulenin 110-119 caspase 9 Homo sapiens 18-27 17877200-4 2007 The expression of caspase 9 was increased markedly, indicating that mitochondria pathway played a key role in cerulenin inducing apoptosis and TRAF2 expression change suggested that nuclear factor (NF) participates in cerulenin inducing apoptosis. Cerulenin 218-227 caspase 9 Homo sapiens 18-27 17877200-4 2007 The expression of caspase 9 was increased markedly, indicating that mitochondria pathway played a key role in cerulenin inducing apoptosis and TRAF2 expression change suggested that nuclear factor (NF) participates in cerulenin inducing apoptosis. Cerulenin 218-227 TNF receptor associated factor 2 Homo sapiens 143-148 17168665-2 2006 Since the pioneering observation that inhibition of FASN activity by the mycotoxin cerulenin preferentially kills cancer cells and retards the growth of tumors in xenografts models, numerous in vitro and in vivo studies have confirmed the potential of FASN as a target for antineoplastic intervention. Cerulenin 83-92 fatty acid synthase Homo sapiens 52-56 17409636-3 2007 In this study, we tested this for ruminants by examining the effect of cerulenin, an inhibitor of de novo fatty acid synthesis at the step from malonyl CoA to palmitate, on leptin production by cultured bovine adipocytes derived from intermuscular fat. Cerulenin 71-80 leptin Bos taurus 173-179 17409636-7 2007 In media with high glucose concentrations, cerulenin enhanced leptin secretion. Cerulenin 43-52 leptin Bos taurus 62-68 17242430-2 2007 The beta-ketoacyl [ACP] synthase (KAS) moiety of the mitochondrial FAS (mtKAS) is targeted by the antibiotic cerulenin and possibly by the other antibiotics inhibiting prokaryotic KASes: thiolactomycin, platensimycin, and the alpha-methylene butyrolactone, C75. Cerulenin 109-118 3-oxoacyl-ACP synthase, mitochondrial Homo sapiens 4-32 17210760-2 2007 The present study was conducted to investigate the effects of several energy balance-related factors (leptin, cerulenin, food deprivation, genotype, and gender) on SCD gene expression in chickens. Cerulenin 110-119 stearoyl-CoA desaturase Gallus gallus 164-167 17210760-11 2007 Leptin increased SCD gene expression in chicken liver (P < 0.05), whereas cerulenin decreased SCD mRNA levels in muscle. Cerulenin 77-86 stearoyl-CoA desaturase Gallus gallus 97-100 17210760-15 2007 In conclusion, SCD is ubiquitously expressed in chickens and it is regulated by leptin, cerulenin, nutritional state, and gender in a tissue-specific manner. Cerulenin 88-97 stearoyl-CoA desaturase Gallus gallus 15-18 16969344-3 2006 Incubating glioma cells with the FAS inhibitor cerulenin decreased endogenous fatty acid synthesis by approximately 50%. Cerulenin 47-56 fatty acid synthase Homo sapiens 33-36 16969344-5 2006 Increased apoptotic cell death and PARP cleavage were observed in U251 and SNB-19 cells treated with cerulenin, which was independent of the death receptor pathway. Cerulenin 101-110 collagen type XI alpha 2 chain Homo sapiens 35-39 17343199-1 2006 OBJECTIVE: To determine whether fatty acid synthase (FAS) is expressed in human multiple myeloma( MM) cells and investigate the proliferation inhibition effect of fatty acid synthase inhibitor cerulenin on multiple myeloma cell line U266 and its mechanism. Cerulenin 193-202 fatty acid synthase Homo sapiens 163-182 17343199-7 2006 When U266 cells were treated with 20 pjg/ml cerulenin for 12 h and 24 h, the early apoptosis rate revealed by Annexin V/PI were 56. Cerulenin 44-53 annexin A5 Homo sapiens 110-119 16969344-6 2006 Overexpressing Bcl-2 inhibited cerulenin-mediated cell death. Cerulenin 31-40 BCL2 apoptosis regulator Homo sapiens 15-20 16455759-8 2006 Cerulenin administration significantly reduced food intake by 23 to 34% (P < 0.05 to P < 0.0001) and downregulated FAS and melanocortin receptors 1, 4, and 5 gene expression (P < 0.05). Cerulenin 0-9 melanocortin 1 receptor Gallus gallus 121-163 16546963-6 2006 In MDA-MB468 cells, cerulenin- and LY294002-mediated apoptosis was associated with caspase-3 activation and the release of cytochrome c from mitochondria to cytosol. Cerulenin 20-29 caspase 3 Homo sapiens 83-92 16569853-4 2006 Forced MDR1 overexpression resulted in increased resistance to the putative Mdr1p substrates cerulenin and brefeldin A, and this resistance did not depend on the additional alterations which occurred during drug resistance development in the clinical isolates. Cerulenin 93-102 ATP binding cassette subfamily B member 1 Homo sapiens 7-11 16546963-6 2006 In MDA-MB468 cells, cerulenin- and LY294002-mediated apoptosis was associated with caspase-3 activation and the release of cytochrome c from mitochondria to cytosol. Cerulenin 20-29 cytochrome c, somatic Homo sapiens 123-135 16546963-8 2006 Treatment of cells with cerulenin and LY294002 down-regulated the protein levels of X chromosome-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis 1 (cIAP-1), and Akt, whereas the levels of mitogen-activated protein/extracellular signal-regulated kinase kinase and other antiapoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xl) did not change. Cerulenin 24-33 X-linked inhibitor of apoptosis Homo sapiens 84-126 16546963-8 2006 Treatment of cells with cerulenin and LY294002 down-regulated the protein levels of X chromosome-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis 1 (cIAP-1), and Akt, whereas the levels of mitogen-activated protein/extracellular signal-regulated kinase kinase and other antiapoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xl) did not change. Cerulenin 24-33 X-linked inhibitor of apoptosis Homo sapiens 128-132 16546963-8 2006 Treatment of cells with cerulenin and LY294002 down-regulated the protein levels of X chromosome-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis 1 (cIAP-1), and Akt, whereas the levels of mitogen-activated protein/extracellular signal-regulated kinase kinase and other antiapoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xl) did not change. Cerulenin 24-33 baculoviral IAP repeat containing 2 Homo sapiens 135-168 16546963-8 2006 Treatment of cells with cerulenin and LY294002 down-regulated the protein levels of X chromosome-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis 1 (cIAP-1), and Akt, whereas the levels of mitogen-activated protein/extracellular signal-regulated kinase kinase and other antiapoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xl) did not change. Cerulenin 24-33 baculoviral IAP repeat containing 2 Homo sapiens 170-176 16546963-8 2006 Treatment of cells with cerulenin and LY294002 down-regulated the protein levels of X chromosome-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis 1 (cIAP-1), and Akt, whereas the levels of mitogen-activated protein/extracellular signal-regulated kinase kinase and other antiapoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xl) did not change. Cerulenin 24-33 AKT serine/threonine kinase 1 Homo sapiens 183-186 16546963-8 2006 Treatment of cells with cerulenin and LY294002 down-regulated the protein levels of X chromosome-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis 1 (cIAP-1), and Akt, whereas the levels of mitogen-activated protein/extracellular signal-regulated kinase kinase and other antiapoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xl) did not change. Cerulenin 24-33 BCL2 apoptosis regulator Homo sapiens 305-310 16546963-8 2006 Treatment of cells with cerulenin and LY294002 down-regulated the protein levels of X chromosome-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis 1 (cIAP-1), and Akt, whereas the levels of mitogen-activated protein/extracellular signal-regulated kinase kinase and other antiapoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xl) did not change. Cerulenin 24-33 BCL2 apoptosis regulator Homo sapiens 328-333 16546963-8 2006 Treatment of cells with cerulenin and LY294002 down-regulated the protein levels of X chromosome-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis 1 (cIAP-1), and Akt, whereas the levels of mitogen-activated protein/extracellular signal-regulated kinase kinase and other antiapoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xl) did not change. Cerulenin 24-33 BCL2 like 1 Homo sapiens 338-344 16546963-9 2006 Interestingly, the nonspecific caspase inhibitor, z-VAD-FMK, inhibited the down-regulation of Akt, XIAP, and cIAP-1 in cerulenin- and LY294002-treated cells. Cerulenin 119-128 AKT serine/threonine kinase 1 Homo sapiens 94-97 16546963-9 2006 Interestingly, the nonspecific caspase inhibitor, z-VAD-FMK, inhibited the down-regulation of Akt, XIAP, and cIAP-1 in cerulenin- and LY294002-treated cells. Cerulenin 119-128 X-linked inhibitor of apoptosis Homo sapiens 99-103 16546963-9 2006 Interestingly, the nonspecific caspase inhibitor, z-VAD-FMK, inhibited the down-regulation of Akt, XIAP, and cIAP-1 in cerulenin- and LY294002-treated cells. Cerulenin 119-128 baculoviral IAP repeat containing 2 Homo sapiens 109-115 16546963-10 2006 In conclusion, these studies show that inhibition of PI3K can sensitize cerulenin-induced apoptosis in MBA-MB468 breast cancer cells via activation of caspases, down-regulation of antiapoptotic proteins, such as XIAP, cIAP-1 and Akt, and possibly, activation of Bak in mitochondria. Cerulenin 72-81 X-linked inhibitor of apoptosis Homo sapiens 212-216 16546963-10 2006 In conclusion, these studies show that inhibition of PI3K can sensitize cerulenin-induced apoptosis in MBA-MB468 breast cancer cells via activation of caspases, down-regulation of antiapoptotic proteins, such as XIAP, cIAP-1 and Akt, and possibly, activation of Bak in mitochondria. Cerulenin 72-81 baculoviral IAP repeat containing 2 Homo sapiens 218-224 16546963-10 2006 In conclusion, these studies show that inhibition of PI3K can sensitize cerulenin-induced apoptosis in MBA-MB468 breast cancer cells via activation of caspases, down-regulation of antiapoptotic proteins, such as XIAP, cIAP-1 and Akt, and possibly, activation of Bak in mitochondria. Cerulenin 72-81 AKT serine/threonine kinase 1 Homo sapiens 229-232 16546963-10 2006 In conclusion, these studies show that inhibition of PI3K can sensitize cerulenin-induced apoptosis in MBA-MB468 breast cancer cells via activation of caspases, down-regulation of antiapoptotic proteins, such as XIAP, cIAP-1 and Akt, and possibly, activation of Bak in mitochondria. Cerulenin 72-81 BCL2 antagonist/killer 1 Homo sapiens 262-265 15878185-3 2005 Inhibition of FAS using cerulenin or synthetic FAS inhibitors such as C75 reduces food intake and induces profound reversible weight loss. Cerulenin 24-33 fatty acid synthase Homo sapiens 14-17 16546963-0 2006 Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis. Cerulenin 110-119 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta Homo sapiens 18-47 16546963-0 2006 Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis. Cerulenin 110-119 AKT serine/threonine kinase 1 Homo sapiens 48-51 16546963-4 2006 Here, we tested whether inhibition of PI3K/Akt pathway would sensitize cancer cells to cerulenin-induced apoptosis. Cerulenin 87-96 AKT serine/threonine kinase 1 Homo sapiens 43-46 16135509-8 2005 A 1.7-fold increased amount of TAG enriched in myristic and palmitic acids and the reduced mobilization rate of TAG from tgl4Delta in the presence of the fatty acid synthesis inhibitor cerulenin demonstrated the lipolytic function of Tgl4p in vivo. Cerulenin 185-194 triacylglycerol lipase Saccharomyces cerevisiae S288C 234-239 15958487-8 2005 The targeting of Tsc13p-GFP into NV junctions is perturbed by cerulenin, suggesting that its binding to Nvj1p depends on the availability of fatty acid substrates. Cerulenin 62-71 trans-2-enoyl-CoA reductase (NADPH) TSC13 Saccharomyces cerevisiae S288C 17-23 15958487-8 2005 The targeting of Tsc13p-GFP into NV junctions is perturbed by cerulenin, suggesting that its binding to Nvj1p depends on the availability of fatty acid substrates. Cerulenin 62-71 Nvj1p Saccharomyces cerevisiae S288C 104-109 15715522-9 2005 These results differentiate inactivation by C75 from that by cerulenin, which only inactivates the beta-ketoacyl synthase activity of FAS, by forming an adduct with an active-site cysteine. Cerulenin 61-70 fatty acid synthase Rattus norvegicus 134-137 15806173-6 2005 Treatment with LY294002 abolished AKT activity and potentiated apoptosis induced by FAS inhibitors cerulenin or C75 only in cells with constitutively active AKT, suggesting that constitutive activation of AKT protects against FAS inhibitor-induced cell death. Cerulenin 99-108 fatty acid synthase Homo sapiens 84-87 15806173-7 2005 Furthermore, inhibition of FAS activity by cerulenin or C75 resulted in downregulation of phospho-AKT, which preceded the induction of apoptosis. Cerulenin 43-52 fatty acid synthase Homo sapiens 27-30 15806173-7 2005 Furthermore, inhibition of FAS activity by cerulenin or C75 resulted in downregulation of phospho-AKT, which preceded the induction of apoptosis. Cerulenin 43-52 AKT serine/threonine kinase 1 Homo sapiens 98-101 15974853-8 2005 FAS activity was blocked by the specific inhibitor cerulenin. Cerulenin 51-60 fatty acid synthase Homo sapiens 0-3 15707993-5 2005 A non-toxic concentration of each enniatin (5 microg/ml, approximately 7.8 microM) strongly inhibited a Pdr5p-mediated efflux of cycloheximide or cerulenin in Pdr5p-overexpressing cells. Cerulenin 146-155 ATP-binding cassette multidrug transporter PDR5 Saccharomyces cerevisiae S288C 104-109 15707993-5 2005 A non-toxic concentration of each enniatin (5 microg/ml, approximately 7.8 microM) strongly inhibited a Pdr5p-mediated efflux of cycloheximide or cerulenin in Pdr5p-overexpressing cells. Cerulenin 146-155 ATP-binding cassette multidrug transporter PDR5 Saccharomyces cerevisiae S288C 159-164 15974853-11 2005 In addition, the FAS inhibitor cerulenin was able to significantly reduce the proliferation of both NG and HGF cells. Cerulenin 31-40 fatty acid synthase Homo sapiens 17-20 15590268-6 2004 Considering difference in the site of action of bezafibrate and cerulenin along fatty acid synthesis pathway, one plausible explanation is that malonyl-CoA levels act as a signal of fuel availability to trigger leptin synthesis and/or secretion in adipocytes. Cerulenin 64-73 leptin Rattus norvegicus 211-217 15583825-6 2005 Treatment with either cerulenin or C75 induced TP53 protein accumulation at 24 h in MCF-7 cells. Cerulenin 22-31 tumor protein p53 Homo sapiens 47-51 15583825-7 2005 To determine whether the up-regulation of TP53 following exposure to cerulenin or C75 was solely due to inhibition of endogenous fatty acid metabolism, we first evaluated the cytotoxic response to chemical FAS blockers on MCF-7 cells in which FAS gene expression was previously silenced by using the highly sequence-specific mechanism of RNA interference. Cerulenin 69-78 tumor protein p53 Homo sapiens 42-46 15617971-3 2005 The effects of cerulenin, a specific, potent, noncompetitive inhibitor of fatty acid synthase (FAS), on growth of TCA-83 cells and normal gingival fibroblasts was determined by the MTT method, and the effect of cerulenin on apoptosis was determined by electrophoresis of cellular DNA. Cerulenin 15-24 fatty acid synthase Homo sapiens 74-93 15617971-3 2005 The effects of cerulenin, a specific, potent, noncompetitive inhibitor of fatty acid synthase (FAS), on growth of TCA-83 cells and normal gingival fibroblasts was determined by the MTT method, and the effect of cerulenin on apoptosis was determined by electrophoresis of cellular DNA. Cerulenin 15-24 fatty acid synthase Homo sapiens 95-98 15486081-7 2004 Overexpression of Cdr1p in C. albicans FL3 conferred resistance to structurally unrelated chemicals such as terbinafine, brefeldin A, cerulenin and nigericin as well as to azole antifungal agents, but not resistance to polyene antibiotics. Cerulenin 134-143 cerebellar degeneration related protein 1 Homo sapiens 18-23 15390078-4 2004 Remarkably, pharmacological FAS blockade using the mycotoxin cerulenin or the novel small compound C75 completely suppressed the state of Her-2/neu-induced malignant transformation by inhibiting the ability of NIH-3T3/Her-2 cells to grow under either anchorage-independent (i.e., to form colonies in soft agar) or low-serum monolayer conditions. Cerulenin 61-70 fatty acid synthase Homo sapiens 28-31 15390078-4 2004 Remarkably, pharmacological FAS blockade using the mycotoxin cerulenin or the novel small compound C75 completely suppressed the state of Her-2/neu-induced malignant transformation by inhibiting the ability of NIH-3T3/Her-2 cells to grow under either anchorage-independent (i.e., to form colonies in soft agar) or low-serum monolayer conditions. Cerulenin 61-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-143 15390078-4 2004 Remarkably, pharmacological FAS blockade using the mycotoxin cerulenin or the novel small compound C75 completely suppressed the state of Her-2/neu-induced malignant transformation by inhibiting the ability of NIH-3T3/Her-2 cells to grow under either anchorage-independent (i.e., to form colonies in soft agar) or low-serum monolayer conditions. Cerulenin 61-70 erb-b2 receptor tyrosine kinase 2 Homo sapiens 144-147 15254710-4 2004 Specifically, we examined the ability of the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, to enhance the cytotoxic effects of vinorelbine (Navelbine), a derivative of vinca alkaloid that interferes with tubulin assembly and exhibits activity against metastatic breast cancer. Cerulenin 55-64 fatty acid synthase Homo sapiens 108-111 15307831-1 2004 Cerulenin has been shown to reduce body weight and hepatic steatosis in murine models of obesity by inhibiting fatty acid synthase (FAS). Cerulenin 0-9 fatty acid synthase Mus musculus 111-130 15307831-1 2004 Cerulenin has been shown to reduce body weight and hepatic steatosis in murine models of obesity by inhibiting fatty acid synthase (FAS). Cerulenin 0-9 fatty acid synthase Mus musculus 132-135 15172643-7 2004 In addition, the specific inhibitor of FAS activity cerulenin was able to significantly reduce the proliferation of oral SCC cells. Cerulenin 52-61 fatty acid synthase Homo sapiens 39-42 15172643-7 2004 In addition, the specific inhibitor of FAS activity cerulenin was able to significantly reduce the proliferation of oral SCC cells. Cerulenin 52-61 serpin family B member 3 Homo sapiens 121-124 15044358-0 2004 Carnitine palmitoyltransferase-1 (CPT-1) activity stimulation by cerulenin via sympathetic nervous system activation overrides cerulenin"s peripheral effect. Cerulenin 65-74 carnitine palmitoyltransferase 1b, muscle Mus musculus 0-32 15235125-3 2004 Pharmacological FAS inhibitors cerulenin and C75 were found to suppress p185(HER2) oncoprotein expression and tyrosine-kinase activity in breast and ovarian HER2 overexpressors. Cerulenin 31-40 fatty acid synthase Homo sapiens 16-19 15235125-3 2004 Pharmacological FAS inhibitors cerulenin and C75 were found to suppress p185(HER2) oncoprotein expression and tyrosine-kinase activity in breast and ovarian HER2 overexpressors. Cerulenin 31-40 eukaryotic translation initiation factor 3 subunit A Homo sapiens 72-76 15235125-3 2004 Pharmacological FAS inhibitors cerulenin and C75 were found to suppress p185(HER2) oncoprotein expression and tyrosine-kinase activity in breast and ovarian HER2 overexpressors. Cerulenin 31-40 erb-b2 receptor tyrosine kinase 2 Homo sapiens 77-81 15044358-0 2004 Carnitine palmitoyltransferase-1 (CPT-1) activity stimulation by cerulenin via sympathetic nervous system activation overrides cerulenin"s peripheral effect. Cerulenin 65-74 carnitine palmitoyltransferase 1b, muscle Mus musculus 34-39 15044358-0 2004 Carnitine palmitoyltransferase-1 (CPT-1) activity stimulation by cerulenin via sympathetic nervous system activation overrides cerulenin"s peripheral effect. Cerulenin 127-136 carnitine palmitoyltransferase 1b, muscle Mus musculus 0-32 15044358-0 2004 Carnitine palmitoyltransferase-1 (CPT-1) activity stimulation by cerulenin via sympathetic nervous system activation overrides cerulenin"s peripheral effect. Cerulenin 127-136 carnitine palmitoyltransferase 1b, muscle Mus musculus 34-39 15044358-4 2004 Cerulenin"s effect on CPT-1 activity was biphasic in the liver and muscle: early suppression during the first 1 h and late stimulation in the 3-5 h after ip treatment. Cerulenin 0-9 carnitine palmitoyltransferase 1b, muscle Mus musculus 22-27 15044358-5 2004 In vitro cerulenin treatment reduced CPT-1 activity, which was overcome by cotreating with catecholamine. Cerulenin 9-18 carnitine palmitoyltransferase 1b, muscle Mus musculus 37-42 15044358-6 2004 Intracerebroventricular injection of cerulenin increased CPT-1 activity significantly in soleus muscle, and this effect was sustained for up to 3 h. Pretreatment with alpha-methyl-p-tyrosine inhibited the cerulenin-induced increase in core temperature and the late-phase stimulating effect of cerulenin on CPT-1 activity. Cerulenin 37-46 carnitine palmitoyltransferase 1b, muscle Mus musculus 57-62 15044358-6 2004 Intracerebroventricular injection of cerulenin increased CPT-1 activity significantly in soleus muscle, and this effect was sustained for up to 3 h. Pretreatment with alpha-methyl-p-tyrosine inhibited the cerulenin-induced increase in core temperature and the late-phase stimulating effect of cerulenin on CPT-1 activity. Cerulenin 37-46 carnitine palmitoyltransferase 1b, muscle Mus musculus 306-311 15044358-8 2004 In vivo cerulenin treatment enhanced muscle CPT-1 activity in monosodium glutamate-treated arcuate nucleus lesioned mice but not in gold thioglucose-treated ventromedial hypothalamus lesioned mice. Cerulenin 8-17 carnitine palmitoyltransferase 1b, muscle Mus musculus 44-49 15044358-9 2004 These findings suggest that cerulenin-induced late-phase stimulating effects on CPT-1 activity and energy expenditure is mediated by the activation of innervated sympathetic nervous system neurons through the firing of undefined neurons of the ventromedial hypothalamus, rather than the arcuate nucleus. Cerulenin 28-37 carnitine palmitoyltransferase 1b, muscle Mus musculus 80-85 15047835-7 2004 Two specific FAS inhibitors, cerulenin and C75, prevent R activation of IE (Z) and early (BMRF1) lytic EBV proteins in Jijoye cells. Cerulenin 29-38 fatty acid synthase Homo sapiens 13-16 15138577-14 2004 Interestingly, a long-term exposure to pharmacological inhibitors of FAS activity cerulenin [(2S,3R) 2,3-epoxy-4-oxo-7E,10E-dodecadienamide] or C75 also resulted in a significant reduction of FAS accumulation. Cerulenin 82-91 fatty acid synthase Homo sapiens 69-72 15138577-14 2004 Interestingly, a long-term exposure to pharmacological inhibitors of FAS activity cerulenin [(2S,3R) 2,3-epoxy-4-oxo-7E,10E-dodecadienamide] or C75 also resulted in a significant reduction of FAS accumulation. Cerulenin 82-91 fatty acid synthase Homo sapiens 192-195 15047835-7 2004 Two specific FAS inhibitors, cerulenin and C75, prevent R activation of IE (Z) and early (BMRF1) lytic EBV proteins in Jijoye cells. Cerulenin 29-38 BMRF1 Human gammaherpesvirus 4 90-95 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Cerulenin 60-69 fatty acid synthase Homo sapiens 113-116 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Cerulenin 60-69 erb-b2 receptor tyrosine kinase 2 Homo sapiens 160-166 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Cerulenin 60-69 erb-b2 receptor tyrosine kinase 2 Homo sapiens 168-171 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Cerulenin 60-69 erb-b2 receptor tyrosine kinase 2 Homo sapiens 257-263 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Cerulenin 60-69 erb-b2 receptor tyrosine kinase 2 Homo sapiens 265-268 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Cerulenin 60-69 erb-b2 receptor tyrosine kinase 2 Homo sapiens 160-171 14615481-6 2004 Cerulenin, a FAS inhibitor, causes a similar biphasic change in ATP levels, although levels do not exceed control. Cerulenin 0-9 fatty acid synthase Homo sapiens 13-16 14745185-1 2004 Point mutation of Gly1250Ser (1250S) of the yeast fatty acid synthase gene FAS2 confers cerulenin resistance. Cerulenin 88-97 trifunctional fatty acid synthase subunit FAS2 Saccharomyces cerevisiae S288C 75-79 14767544-10 2004 Pharmacological inhibition of FAS activity by the natural antibiotic cerulenin [(2S,3R)-2,3-epoxy-4-oxo-7E,10E-dodecadienamide] resulted in a dose-dependent cytotoxicity which positively paralleled the endogenous level of FAS. Cerulenin 69-78 fatty acid synthase Homo sapiens 222-225 14767544-16 2004 In SK-Br3 cells, cerulenin-induced inhibition of FAS activity resulted in down-regulation of p53, and up-regulation of cyclin-dependent kinase inhibitor (CDKi) p21WAF1/CIP1. Cerulenin 17-26 fatty acid synthase Homo sapiens 49-52 14767544-16 2004 In SK-Br3 cells, cerulenin-induced inhibition of FAS activity resulted in down-regulation of p53, and up-regulation of cyclin-dependent kinase inhibitor (CDKi) p21WAF1/CIP1. Cerulenin 17-26 tumor protein p53 Homo sapiens 93-96 14767544-16 2004 In SK-Br3 cells, cerulenin-induced inhibition of FAS activity resulted in down-regulation of p53, and up-regulation of cyclin-dependent kinase inhibitor (CDKi) p21WAF1/CIP1. Cerulenin 17-26 cyclin dependent kinase inhibitor 1A Homo sapiens 160-172 14767544-17 2004 Treatment with cerulenin or a novel small-molecule inhibitor of FAS C75 resulted in a dramatic accumulation of CDKi p27KIP1, which was accompanied by a noteworthy translocation of p27KIP1 from cytosol to cell nuclei. Cerulenin 15-24 fatty acid synthase Homo sapiens 64-67 14767544-17 2004 Treatment with cerulenin or a novel small-molecule inhibitor of FAS C75 resulted in a dramatic accumulation of CDKi p27KIP1, which was accompanied by a noteworthy translocation of p27KIP1 from cytosol to cell nuclei. Cerulenin 15-24 cyclin dependent kinase inhibitor 1B Homo sapiens 116-123 14767544-17 2004 Treatment with cerulenin or a novel small-molecule inhibitor of FAS C75 resulted in a dramatic accumulation of CDKi p27KIP1, which was accompanied by a noteworthy translocation of p27KIP1 from cytosol to cell nuclei. Cerulenin 15-24 cyclin dependent kinase inhibitor 1B Homo sapiens 180-187 14563479-3 2003 Preincubation of HIT-T15 or INS-1 cells with cerulenin (CER, 134 microM; 3 hr), an inhibitor of protein palmitoylation, significantly reduced (-95%) IL-1 beta-induced NO release from these cells. Cerulenin 45-54 interleukin 1 beta Rattus norvegicus 149-158 14563479-3 2003 Preincubation of HIT-T15 or INS-1 cells with cerulenin (CER, 134 microM; 3 hr), an inhibitor of protein palmitoylation, significantly reduced (-95%) IL-1 beta-induced NO release from these cells. Cerulenin 56-59 interleukin 1 beta Rattus norvegicus 149-158 12957363-4 2003 To test this hypothesis, hypothalamic sections from mice that were fed or injected with the fatty acid synthase inhibitor cerulenin were examined for Fos (a marker for neuronal activation) and POMC product immunoreactivity and compared with similarly processed sections from leptin-injected mice. Cerulenin 122-131 fatty acid synthase Mus musculus 92-111 14767544-10 2004 Pharmacological inhibition of FAS activity by the natural antibiotic cerulenin [(2S,3R)-2,3-epoxy-4-oxo-7E,10E-dodecadienamide] resulted in a dose-dependent cytotoxicity which positively paralleled the endogenous level of FAS. Cerulenin 69-78 fatty acid synthase Homo sapiens 30-33 12957363-0 2003 The fatty acid synthase inhibitor cerulenin and feeding, like leptin, activate hypothalamic pro-opiomelanocortin (POMC) neurons. Cerulenin 34-43 fatty acid synthase Mus musculus 4-23 12957363-0 2003 The fatty acid synthase inhibitor cerulenin and feeding, like leptin, activate hypothalamic pro-opiomelanocortin (POMC) neurons. Cerulenin 34-43 pro-opiomelanocortin-alpha Mus musculus 92-112 12957363-0 2003 The fatty acid synthase inhibitor cerulenin and feeding, like leptin, activate hypothalamic pro-opiomelanocortin (POMC) neurons. Cerulenin 34-43 pro-opiomelanocortin-alpha Mus musculus 114-118 12957363-7 2003 Injection with cerulenin, like feeding and leptin, also increased Fos immunoreactivity in the lateral peri-arcuate area (P<0.03) and, more specifically, in neurons expressing POMC. Cerulenin 15-24 FBJ osteosarcoma oncogene Mus musculus 66-69 12957363-7 2003 Injection with cerulenin, like feeding and leptin, also increased Fos immunoreactivity in the lateral peri-arcuate area (P<0.03) and, more specifically, in neurons expressing POMC. Cerulenin 15-24 pro-opiomelanocortin-alpha Mus musculus 178-182 12957363-8 2003 In contrast, injection with cerulenin had no grossly observable effects on cortical Fos immunoreactivity and appeared to suppress fasting-induced Fos immunoreactivity by about 35% (although the decrease did not reach statistical significance) in the medial arcuate nucleus, an area associated with anabolic responses such as increased food intake. Cerulenin 28-37 FBJ osteosarcoma oncogene Mus musculus 146-149 12957363-9 2003 Injection with cerulenin also decreased Fos immunoreactivity in the granular layer of the dentate gyrus of the hippocampus by about 30% (P<0.05), further suggesting that cerulenin does not non-specifically activate wide varieties of neurons. Cerulenin 15-24 FBJ osteosarcoma oncogene Mus musculus 40-43 12957363-10 2003 These results suggest that activation of hypothalamic POMC neurons may help to mediate some of the catabolic effects associated with feeding, cerulenin and leptin. Cerulenin 142-151 pro-opiomelanocortin-alpha Mus musculus 54-58 12682047-7 2003 Most importantly, experiments in vivo using the fatty acid synthesis inhibitor cerulenin demonstrated that deletion of TGL3 resulted in a decreased mobilization of TAG from lipid particles. Cerulenin 79-88 bifunctional triglyceride lipase/lysophosphatidylethanolamine acyltransferase Saccharomyces cerevisiae S288C 119-123 12782313-8 2003 Cerulenin, an acylation inhibitor, abolished the palmitate effect on protein levels and phosphorylation of insulin receptor. Cerulenin 0-9 insulin receptor Rattus norvegicus 107-123 11754479-0 2002 Use of a YAP1 overexpression cassette conferring specific resistance to cerulenin and cycloheximide as an efficient selectable marker in the yeast Saccharomyces cerevisiae. Cerulenin 72-81 DNA-binding transcription factor YAP1 Saccharomyces cerevisiae S288C 9-13 12515321-0 2002 Effect of 2-fluoropalmitate, cerulenin and tunicamycin on the palmitoylation and intracellular translocation of myelin proteolipid protein. Cerulenin 29-38 proteolipid protein 1 Rattus norvegicus 112-138 12213216-6 2002 H-ras transformation sensitized MCF-10a cells to the FAS inhibitors cerulenin and C-75. Cerulenin 68-77 fatty acid synthase Homo sapiens 53-56 12181752-6 2002 The significance of the mitochondrial pathway for the cerulenin-mediated apoptosis was confirmed by the rapid mitochondrial release of cytochrome c both in wild-type p53 and mutant cell lines. Cerulenin 54-63 cytochrome c, somatic Homo sapiens 135-147 12181752-6 2002 The significance of the mitochondrial pathway for the cerulenin-mediated apoptosis was confirmed by the rapid mitochondrial release of cytochrome c both in wild-type p53 and mutant cell lines. Cerulenin 54-63 tumor protein p53 Homo sapiens 166-169 11935210-1 2002 BACKGROUND AND PURPOSE: Human type I fatty acid synthase has been proposed as a chemotherapeutic target for the treatment of breast cancer based on the inactivation of human beta-ketoacyl synthase activity by cerulenin. Cerulenin 209-218 fatty acid synthase Homo sapiens 37-56 12820377-9 2003 Finally, the FAS inhibitor cerulenin was investigated for its ability to suppress tumor cell growth. Cerulenin 27-36 fatty acid synthase Homo sapiens 13-16 12820377-11 2003 Annexin V assays revealed that cerulenin initiated apoptosis. Cerulenin 31-40 annexin A5 Homo sapiens 0-9 12820377-12 2003 The antineoplastic properties of cerulenin documented here are consistent with prior studies showing its cytotoxic effects upon other types of cancer cells and illustrate the potential utility of FAS inhibition as a novel chemotherapeutic approach. Cerulenin 33-42 fatty acid synthase Homo sapiens 196-199 12181752-1 2002 Cerulenin, a fungal metabolite, is known to be a specific inhibitor of fatty acid synthase. Cerulenin 0-9 fatty acid synthase Homo sapiens 71-90 12181752-2 2002 Here we report that cerulenin is an effective inducer of apoptosis in different wild-type p53 and mutant p53 tumor cell lines, whereas normal human keratinocytes and fibroblasts are resistant to the apoptotic effect. Cerulenin 20-29 tumor protein p53 Homo sapiens 90-93 12181752-2 2002 Here we report that cerulenin is an effective inducer of apoptosis in different wild-type p53 and mutant p53 tumor cell lines, whereas normal human keratinocytes and fibroblasts are resistant to the apoptotic effect. Cerulenin 20-29 tumor protein p53 Homo sapiens 105-108 11754479-4 2002 Yeast cells containing PGKp-YAP1 were resistant to cycloheximide, a protein synthesis inhibitor, and also to cerulenin, a fatty acid synthesis inhibitor, but not to other drugs tested. Cerulenin 109-118 DNA-binding transcription factor YAP1 Saccharomyces cerevisiae S288C 28-32 11754479-5 2002 The transformation efficiency of PGKp-YAP1 using cerulenin selection was comparable to that using a URA3 auxotrophic marker when low concentrations of cerulenin were used. Cerulenin 49-58 DNA-binding transcription factor YAP1 Saccharomyces cerevisiae S288C 38-42 11758940-5 2001 The purified inhibitor (molecular weight = 1,193 by FAB-MS) inhibited a Pdr5-mediated efflux of cycloheximide and cerulenin. Cerulenin 114-123 ATP-binding cassette multidrug transporter PDR5 Saccharomyces cerevisiae S288C 72-76 11597568-3 2001 We have described previously the synthesis of cerulenin analogs including cis-2,3-epoxy-4-oxononadecanamide (16C) and cis-2,3-epoxy-4-oxododecanamide (9C) that inhibit protein palmitoylation (Lawrence et al., J Med Chem 1999;42:4932-41), most likely through covalent alkylation of protein palmitoyltransferase. Cerulenin 46-55 suppressor of cytokine signaling 2 Homo sapiens 74-79 11597568-3 2001 We have described previously the synthesis of cerulenin analogs including cis-2,3-epoxy-4-oxononadecanamide (16C) and cis-2,3-epoxy-4-oxododecanamide (9C) that inhibit protein palmitoylation (Lawrence et al., J Med Chem 1999;42:4932-41), most likely through covalent alkylation of protein palmitoyltransferase. Cerulenin 46-55 suppressor of cytokine signaling 2 Homo sapiens 118-123 11515543-5 2001 The sensitivity of the indicator strain (delta syr1/erg3 delta pdr5 delta snq2) to the Pdr5 substrates, cycloheximide and cerulenin, was increased 16-fold and 4-fold against wild type, respectively. Cerulenin 122-131 C-5 sterol desaturase Saccharomyces cerevisiae S288C 47-51 11515543-5 2001 The sensitivity of the indicator strain (delta syr1/erg3 delta pdr5 delta snq2) to the Pdr5 substrates, cycloheximide and cerulenin, was increased 16-fold and 4-fold against wild type, respectively. Cerulenin 122-131 C-5 sterol desaturase Saccharomyces cerevisiae S288C 52-56 11515543-5 2001 The sensitivity of the indicator strain (delta syr1/erg3 delta pdr5 delta snq2) to the Pdr5 substrates, cycloheximide and cerulenin, was increased 16-fold and 4-fold against wild type, respectively. Cerulenin 122-131 ATP-binding cassette multidrug transporter PDR5 Saccharomyces cerevisiae S288C 63-67 11515543-5 2001 The sensitivity of the indicator strain (delta syr1/erg3 delta pdr5 delta snq2) to the Pdr5 substrates, cycloheximide and cerulenin, was increased 16-fold and 4-fold against wild type, respectively. Cerulenin 122-131 ATP-binding cassette multidrug transporter PDR5 Saccharomyces cerevisiae S288C 87-91 11515543-6 2001 The screening system is mainly based on the growth inhibition of the PDR5-overexpressed indicator strain with the combination of a sample and cycloheximide or cerulenin. Cerulenin 159-168 ATP-binding cassette multidrug transporter PDR5 Saccharomyces cerevisiae S288C 69-73 11289036-0 2001 Cerulenin mimics effects of leptin on metabolic rate, food intake, and body weight independent of the melanocortin system, but unlike leptin, cerulenin fails to block neuroendocrine effects of fasting. Cerulenin 0-9 leptin Mus musculus 28-34 11289036-1 2001 Cerulenin and a related compound, C75, have recently been reported to reduce food intake and body weight independent of leptin through a mechanism hypothesized, like leptin, to involve hypothalamic nutrition-sensitive neurons. Cerulenin 0-9 leptin Mus musculus 166-172 10880966-5 2000 FAT1 is essential for growth under hypoxic conditions and when cerulenin was included in the culture media in the presence or absence of unsaturated fatty acids. Cerulenin 63-72 long-chain fatty acid transporter FAT1 Saccharomyces cerevisiae S288C 0-4 11866947-1 2000 OBJECTIVE: To determine the effects of fatty acid synthase inhibitor, cerulenin, on tumor growth of human colonic carcinoma (LoVo) in nude mice. Cerulenin 70-79 fatty acid synthase Homo sapiens 39-58 11866947-8 2000 bcl-2 oncoprotein expression rate was significantly lower in cerulenin-treated group in comparing with the control group. Cerulenin 61-70 BCL2 apoptosis regulator Homo sapiens 0-5 11866947-11 2000 The mechanism of cell death may be correlated with apoptosis, and bcl-2 and bax gene may play an important role in regulating cerulenin-induced apoptosis. Cerulenin 126-135 BCL2 apoptosis regulator Homo sapiens 66-71 11866947-11 2000 The mechanism of cell death may be correlated with apoptosis, and bcl-2 and bax gene may play an important role in regulating cerulenin-induced apoptosis. Cerulenin 126-135 BCL2 associated X, apoptosis regulator Homo sapiens 76-79 11245456-1 2001 Fatty acid synthetic metabolism is abnormally elevated in tumor cells, and pharmacological inhibitors of the anabolic enzyme fatty acid synthase (FAS), including the natural product cerulenin and the novel synthetic compound c75, are selective inhibitors of tumor cell growth. Cerulenin 182-191 fatty acid synthase Homo sapiens 125-144 11245456-1 2001 Fatty acid synthetic metabolism is abnormally elevated in tumor cells, and pharmacological inhibitors of the anabolic enzyme fatty acid synthase (FAS), including the natural product cerulenin and the novel synthetic compound c75, are selective inhibitors of tumor cell growth. Cerulenin 182-191 fatty acid synthase Homo sapiens 146-149 11082286-7 2000 Cerulenin and TOFA each inhibited the endogenous synthesis of fatty acids in a dose-dependent manner and each induced increases in both precursor and mature forms of SREBP-1. Cerulenin 0-9 sterol regulatory element binding transcription factor 1 Homo sapiens 166-173 10880966-11 2000 Fat1p and FATP restored growth of fat1Delta cells in the presence of cerulenin and under hypoxic conditions. Cerulenin 69-78 long-chain fatty acid transporter FAT1 Saccharomyces cerevisiae S288C 0-5 10875926-3 2000 Both systemic and intracerebroventricular treatment of mice with fatty acid synthase (FAS) inhibitors (cerulenin and a synthetic compound C75) led to inhibition of feeding and dramatic weight loss. Cerulenin 103-112 fatty acid synthase Mus musculus 65-84 10875926-3 2000 Both systemic and intracerebroventricular treatment of mice with fatty acid synthase (FAS) inhibitors (cerulenin and a synthetic compound C75) led to inhibition of feeding and dramatic weight loss. Cerulenin 103-112 fatty acid synthase Mus musculus 86-89 11866903-8 2000 CONCLUSION: The fatty acid synthase inhibitor, cerulenin, enables to induce cell apoptosis and to suppress the growth of human colonic cancer cells by inhibition of the synthesized fatty acids endogenously in the cancer cells. Cerulenin 47-56 fatty acid synthase Homo sapiens 16-35 11029661-8 2000 Furthermore, cerulenin, an inhibitor of FAS, reduced axonal growth and in vivo palmitoylation of GAP-43 in cultured neurones. Cerulenin 13-22 fatty acid synthase Mus musculus 40-43 11029661-8 2000 Furthermore, cerulenin, an inhibitor of FAS, reduced axonal growth and in vivo palmitoylation of GAP-43 in cultured neurones. Cerulenin 13-22 growth associated protein 43 Mus musculus 97-103 10880966-11 2000 Fat1p and FATP restored growth of fat1Delta cells in the presence of cerulenin and under hypoxic conditions. Cerulenin 69-78 solute carrier family 27 (fatty acid transporter), member 1 Mus musculus 10-14 11876988-0 2000 [Proliferation inhibition and apoptosis induction of K562 cells by fatty acid synthase inhibitor--cerulenin]. Cerulenin 98-107 fatty acid synthase Homo sapiens 67-86 11876988-1 2000 OBJECTIVE: To investigate the effect of fatty acid synthase (FAS) inhibitor--cerulenin on K562 leukemia cells and its mechanism. Cerulenin 77-86 fatty acid synthase Homo sapiens 40-59 11876988-1 2000 OBJECTIVE: To investigate the effect of fatty acid synthase (FAS) inhibitor--cerulenin on K562 leukemia cells and its mechanism. Cerulenin 77-86 fatty acid synthase Homo sapiens 61-64 11876988-6 2000 CONCLUSION: Fatty acid synthase inhibitor--cerulenin inhibits proliferation of K562 cells but not of human fibroblasts. Cerulenin 43-52 fatty acid synthase Homo sapiens 12-31 16232807-4 2000 The disruptant for the FAA1 gene (K701deltafaa1) exhibited a reduced growth rate in a medium containing cerulenin and myristic acid or oleic acid compared with that of the parental strain (K701). Cerulenin 104-113 long-chain fatty acid-CoA ligase FAA1 Saccharomyces cerevisiae S288C 23-27 9788612-1 1998 Pharmacological inhibitors of the anabolic enzyme, fatty acid synthase (FAS), including the natural product cerulenin and the novel compound c75, are selectively cytotoxic to cancer cells via induction of apoptosis, apparently related to the tumor cell phenotype of abnormally elevated fatty acid synthetic metabolism. Cerulenin 108-117 fatty acid synthase Homo sapiens 51-70 10050038-3 1999 Cerulenin, a potent inhibitor of lipid biosynthesis, also induced these chaperones in an Ire1p-dependent manner and limited the production of functional P450Alk1. Cerulenin 0-9 bifunctional endoribonuclease/protein kinase IRE1 Saccharomyces cerevisiae S288C 89-94 10102370-0 1999 YAP1 confers resistance to the fatty acid synthase inhibitor cerulenin through the transporter Flr1p in Saccharomyces cerevisiae. Cerulenin 61-70 DNA-binding transcription factor YAP1 Saccharomyces cerevisiae S288C 0-4 10102370-0 1999 YAP1 confers resistance to the fatty acid synthase inhibitor cerulenin through the transporter Flr1p in Saccharomyces cerevisiae. Cerulenin 61-70 Flr1p Saccharomyces cerevisiae S288C 95-100 16232423-2 1999 A yeast strain exhibiting cerulenin resistance conferred by a dominant mutation of FAS2 was previously shown to produce high levels of a flavor component of Japanese sake. Cerulenin 26-35 trifunctional fatty acid synthase subunit FAS2 Saccharomyces cerevisiae S288C 83-87 16232423-8 1999 This recombination event resulted in loss of the integrated plasmid sequences and the resulting strains should contain a single copy of either wild-type or cerulenin-resistant FAS2. Cerulenin 156-165 trifunctional fatty acid synthase subunit FAS2 Saccharomyces cerevisiae S288C 176-180 10585203-3 1999 We have demonstrated that the natural product cerulenin ([2R,3S]-2,3-epoxy-4-oxo-7,10-trans,trans-dodecadienamide) inhibits the palmitoylation of H-ras- and N-ras-encoded p21s in parallel with inhibition of cell proliferation. Cerulenin 46-55 HRas proto-oncogene, GTPase Homo sapiens 146-151 10585203-3 1999 We have demonstrated that the natural product cerulenin ([2R,3S]-2,3-epoxy-4-oxo-7,10-trans,trans-dodecadienamide) inhibits the palmitoylation of H-ras- and N-ras-encoded p21s in parallel with inhibition of cell proliferation. Cerulenin 46-55 NRAS proto-oncogene, GTPase Homo sapiens 157-162 10585203-3 1999 We have demonstrated that the natural product cerulenin ([2R,3S]-2,3-epoxy-4-oxo-7,10-trans,trans-dodecadienamide) inhibits the palmitoylation of H-ras- and N-ras-encoded p21s in parallel with inhibition of cell proliferation. Cerulenin 46-55 H3 histone pseudogene 16 Homo sapiens 171-174 9788612-1 1998 Pharmacological inhibitors of the anabolic enzyme, fatty acid synthase (FAS), including the natural product cerulenin and the novel compound c75, are selectively cytotoxic to cancer cells via induction of apoptosis, apparently related to the tumor cell phenotype of abnormally elevated fatty acid synthetic metabolism. Cerulenin 108-117 fatty acid synthase Homo sapiens 72-75 9593144-7 1998 The resulting erg6 strains were shown to be hypersusceptible to a number of sterol synthesis and metabolic inhibitors, including terbinafine, tridemorph, fenpropiomorph, fluphenazine, cycloheximide, cerulenin, and brefeldin A. Cerulenin 199-208 sterol 24-C-methyltransferase Saccharomyces cerevisiae S288C 14-18 9660783-7 1998 FAT1 deletion strains exhibited decreased growth on medium containing dextrose, oleic acid, and cerulenin, an inhibitor of fatty acid synthesis. Cerulenin 96-105 long-chain fatty acid transporter FAT1 Saccharomyces cerevisiae S288C 0-4 9581863-5 1998 Inhibition of 67LR formation by cerulenin indicates that acylation is involved in the processing of the receptor. Cerulenin 32-41 ribosomal protein SA Homo sapiens 14-18 9593836-13 1998 Finally, cell lines were treated with the FAS inhibitor cerulenin: almost all breast cancer lines were growth inhibited at significantly lower amounts of drug than normal cell lineages, suggesting that FAS plays a greater role in viability of tumor cells than normal cells. Cerulenin 56-65 fatty acid synthase Homo sapiens 42-45 9593836-13 1998 Finally, cell lines were treated with the FAS inhibitor cerulenin: almost all breast cancer lines were growth inhibited at significantly lower amounts of drug than normal cell lineages, suggesting that FAS plays a greater role in viability of tumor cells than normal cells. Cerulenin 56-65 fatty acid synthase Homo sapiens 202-205 8665507-2 1996 A substantial subset of human breast, ovarian, endometrial, colorectal, and prostatic cancers express elevated levels of fatty acid synthase, the major enzyme required for endogenous fatty acid biosynthesis, and carcinoma lines are growth inhibited by cerulenin, a noncompetitive inhibitor of fatty acid synthase. Cerulenin 252-261 fatty acid synthase Homo sapiens 121-140 9037098-5 1997 The incorporation of radioactivity from [2-14C]malonate into fatty acids and the labeling of ACP were inhibited by cerulenin and required ATP and Mg2+. Cerulenin 115-124 NADH:ubiquinone oxidoreductase subunit AB1 Homo sapiens 93-96 8952473-8 1996 Pretreatment of the wild-type protein with the beta-ketoacyl-ACP synthase inhibitor cerulenin also blocked acylation. Cerulenin 84-93 3-oxoacyl-ACP synthase, mitochondrial Homo sapiens 47-73 8631008-2 1996 Recent studies have shown that the FAS inhibitor, cerulenin, is selectively cytotoxic to cell lines derived from human malignancies, suggesting that those carcinoma cells are dependent upon endogenous fatty acid synthesis for growth. Cerulenin 50-59 fatty acid synthase Homo sapiens 35-38 8631008-7 1996 HL60 cells adapted to growth in serum- and fatty acid-free medium show a dose-dependent sensitivity to cerulenin, which is reversed by palmitate, the major product of FAS, indicating that cerulenin cytotoxicity is mediated through fatty acid starvation. Cerulenin 103-112 fatty acid synthase Homo sapiens 167-170 8631008-7 1996 HL60 cells adapted to growth in serum- and fatty acid-free medium show a dose-dependent sensitivity to cerulenin, which is reversed by palmitate, the major product of FAS, indicating that cerulenin cytotoxicity is mediated through fatty acid starvation. Cerulenin 188-197 fatty acid synthase Homo sapiens 167-170 7962057-6 1994 When Fas is inactivated by a specific inhibitor (cerulenin), NMT1 cells are not viable unless the media is supplemented with long chain fatty acids. Cerulenin 49-58 glycylpeptide N-tetradecanoyltransferase NMT1 Saccharomyces cerevisiae S288C 61-65 7883711-4 1995 Consistent with this is that S. pombe cells harboring bfr1+ on pDB248" are resistant to actinomycin D, cerulenin, and cytochalasin B, as well as to BFA. Cerulenin 103-112 Bfr1p Saccharomyces cerevisiae S288C 54-58 7882421-2 1994 Disruption of YDR1 resulted in hypersensitivity to cycloheximide, cerulenin, compactin, staurosporine and fluphenazine, indicating that YDR1 is an important determinant of cross resistance to apparently-unrelated drugs. Cerulenin 66-75 ATP-binding cassette multidrug transporter PDR5 Saccharomyces cerevisiae S288C 14-18 7882421-5 1994 YDR1 was responsible for cycloheximide, cerulenin and compactin resistance, whereas, SNQ2 was responsible for 4-NQO resistance. Cerulenin 40-49 ATP-binding cassette multidrug transporter PDR5 Saccharomyces cerevisiae S288C 0-4 8022791-6 1994 Supraphysiologic levels of palmitate, 14 microM in dimethyl sulfoxide, significantly reversed the growth inhibition caused by cerulenin at concentrations of up to 5 micrograms/ml, indicating that cerulenin-mediated growth inhibition was due to fatty acid synthase inhibition. Cerulenin 126-135 fatty acid synthase Homo sapiens 244-263 8022791-6 1994 Supraphysiologic levels of palmitate, 14 microM in dimethyl sulfoxide, significantly reversed the growth inhibition caused by cerulenin at concentrations of up to 5 micrograms/ml, indicating that cerulenin-mediated growth inhibition was due to fatty acid synthase inhibition. Cerulenin 196-205 fatty acid synthase Homo sapiens 244-263 8415763-4 1993 This pheromone-stimulated shift depends on the function of STE2 (alpha-factor receptor), STE11 (a protein kinase in the response pathway), and NMT1 (myristoyl-CoA:protein N-myristoyltransferase) genes and uses the existing pool of fatty acids (is not blocked by cerulenin). Cerulenin 262-271 alpha-factor pheromone receptor STE2 Saccharomyces cerevisiae S288C 59-63 8041367-12 1994 Furthermore, a recombinant FAS2 gene, in which the 0.8 Kb EcoRV-HindIII fragment of the wild-type FAS2 gene was replaced with the same region from the mutant, when introduced into FAS2-defective S. cerevisiae complemented the FAS2 phenotype and showed cerulenin resistance. Cerulenin 252-261 trifunctional fatty acid synthase subunit FAS2 Saccharomyces cerevisiae S288C 27-31 8415763-4 1993 This pheromone-stimulated shift depends on the function of STE2 (alpha-factor receptor), STE11 (a protein kinase in the response pathway), and NMT1 (myristoyl-CoA:protein N-myristoyltransferase) genes and uses the existing pool of fatty acids (is not blocked by cerulenin). Cerulenin 262-271 mitogen-activated protein kinase kinase kinase STE11 Saccharomyces cerevisiae S288C 65-94 8415763-4 1993 This pheromone-stimulated shift depends on the function of STE2 (alpha-factor receptor), STE11 (a protein kinase in the response pathway), and NMT1 (myristoyl-CoA:protein N-myristoyltransferase) genes and uses the existing pool of fatty acids (is not blocked by cerulenin). Cerulenin 262-271 glycylpeptide N-tetradecanoyltransferase NMT1 Saccharomyces cerevisiae S288C 143-147 34977875-6 2021 PCa cell growth was significantly inhibited through the decreased AKT signaling pathway by treatment with cerulenin, a chemical FASN inhibitor, which also downregulated PIP, PIP2, and PIP3 but not PI. Cerulenin 106-115 AKT serine/threonine kinase 1 Homo sapiens 66-69 2269328-3 1990 Furthermore, presentation of the insulin fragment as well as presentation of ovalbumin (OVA) was inhibited by treatment of APC with chloroquine, cerulenin or tunicamycin. Cerulenin 145-154 insulin Homo sapiens 33-40 1690152-5 1990 We show here that cerulenin inhibits the action of the HIV-1 proteinase in vitro, using 3 substrates: a synthetic heptapeptide (SQNYPIV) which corresponds to the sequence at the HIV-1 gag p17/p24 junction, a bacterially expressed gag precursor, and purified 66 kDa reverse transcriptase. Cerulenin 18-27 Pr55(Gag) Human immunodeficiency virus 1 184-187 1690152-5 1990 We show here that cerulenin inhibits the action of the HIV-1 proteinase in vitro, using 3 substrates: a synthetic heptapeptide (SQNYPIV) which corresponds to the sequence at the HIV-1 gag p17/p24 junction, a bacterially expressed gag precursor, and purified 66 kDa reverse transcriptase. Cerulenin 18-27 Pr55(Gag) Human immunodeficiency virus 1 230-233 1567893-8 1992 The formation of the 26 kDa proSP-C isoform in CHO/SPC cells and the 24 kDa proSP-C isoform in murine fetal lung was blocked by cerulenin, an inhibitor of fatty acid synthesis. Cerulenin 128-137 protein S (beta) pseudogene Homo sapiens 28-33 1567893-8 1992 The formation of the 26 kDa proSP-C isoform in CHO/SPC cells and the 24 kDa proSP-C isoform in murine fetal lung was blocked by cerulenin, an inhibitor of fatty acid synthesis. Cerulenin 128-137 surfactant protein C Homo sapiens 51-54 1567893-8 1992 The formation of the 26 kDa proSP-C isoform in CHO/SPC cells and the 24 kDa proSP-C isoform in murine fetal lung was blocked by cerulenin, an inhibitor of fatty acid synthesis. Cerulenin 128-137 protein S (beta) pseudogene Homo sapiens 76-81 2157453-6 1990 One explanation for its effect on GRF receptor internalization is that fatty acid acylation of a protein (possibly the receptor) is necessary for internalization, because cerulenin also inhibited internalization of the transferrin receptor which is known to be acylated. Cerulenin 171-180 growth hormone releasing hormone receptor Rattus norvegicus 34-46 2157453-6 1990 One explanation for its effect on GRF receptor internalization is that fatty acid acylation of a protein (possibly the receptor) is necessary for internalization, because cerulenin also inhibited internalization of the transferrin receptor which is known to be acylated. Cerulenin 171-180 transferrin Rattus norvegicus 219-230 34977875-6 2021 PCa cell growth was significantly inhibited through the decreased AKT signaling pathway by treatment with cerulenin, a chemical FASN inhibitor, which also downregulated PIP, PIP2, and PIP3 but not PI. Cerulenin 106-115 fatty acid synthase Homo sapiens 128-132 34977875-6 2021 PCa cell growth was significantly inhibited through the decreased AKT signaling pathway by treatment with cerulenin, a chemical FASN inhibitor, which also downregulated PIP, PIP2, and PIP3 but not PI. Cerulenin 106-115 prolactin induced protein Homo sapiens 169-172 2546911-6 1989 The results suggest that an event which coincides with the Ca2+-mobilization and not Ca2+ per se is important for the induction of O2- generation in the fMLP-stimulated cells and that this step is blocked in cerulenin-treated cells. Cerulenin 208-217 formyl peptide receptor 1 Homo sapiens 153-157 34483846-5 2021 SH-SY5Y cells and cortical neurons exposed to 10 h of OGD and 24 h of reoxygenation displayed prominent cell death when treated with the Acetyl-CoA carboxylase inhibitor TOFA or the fatty acid synthase inhibitor cerulenin. Cerulenin 212-221 fatty acid synthase Homo sapiens 182-201 2546911-3 1989 Generation of superoxide anion (O2-) and mobilization of intracellular Ca2+ in human neutrophils upon exposure to stimuli such as N-formylmethionylleucylphenylalanine (fMLP) were inhibited by the antibiotic cerulenin, which inhibits fatty acid and cholesterol biosynthesis. Cerulenin 207-216 formyl peptide receptor 1 Homo sapiens 168-172 35597782-9 2022 More importantly, knockdown of FASN with FASN shRNA or the inhibitors C75 and Cerulenin dramatically diminished LNM in vivo, suggesting that FASN plays an essential role in LNM of CC and the clinical application potential of FASN inhibitors. Cerulenin 78-87 fatty acid synthase Homo sapiens 31-35 35597782-9 2022 More importantly, knockdown of FASN with FASN shRNA or the inhibitors C75 and Cerulenin dramatically diminished LNM in vivo, suggesting that FASN plays an essential role in LNM of CC and the clinical application potential of FASN inhibitors. Cerulenin 78-87 fatty acid synthase Homo sapiens 141-145 35597782-9 2022 More importantly, knockdown of FASN with FASN shRNA or the inhibitors C75 and Cerulenin dramatically diminished LNM in vivo, suggesting that FASN plays an essential role in LNM of CC and the clinical application potential of FASN inhibitors. Cerulenin 78-87 fatty acid synthase Homo sapiens 225-229 2666407-5 1989 Tryptic digestion of the [3H] cerulenin-treated enzyme gave a radioactive peptide; its amino acid composition was Asx 1, Thr 1, Ser 1, Glx 2, Pro 1, Gly 1, Ala 1, Val 1, Ile 1, and Leu 2. Cerulenin 30-39 homoserine kinase Saccharomyces cerevisiae S288C 121-126 2666407-5 1989 Tryptic digestion of the [3H] cerulenin-treated enzyme gave a radioactive peptide; its amino acid composition was Asx 1, Thr 1, Ser 1, Glx 2, Pro 1, Gly 1, Ala 1, Val 1, Ile 1, and Leu 2. Cerulenin 30-39 O-phospho-L-serine:2-oxoglutarate transaminase Saccharomyces cerevisiae S288C 128-133 2666407-5 1989 Tryptic digestion of the [3H] cerulenin-treated enzyme gave a radioactive peptide; its amino acid composition was Asx 1, Thr 1, Ser 1, Glx 2, Pro 1, Gly 1, Ala 1, Val 1, Ile 1, and Leu 2. Cerulenin 30-39 glutamate 5-kinase Saccharomyces cerevisiae S288C 142-147 2666407-5 1989 Tryptic digestion of the [3H] cerulenin-treated enzyme gave a radioactive peptide; its amino acid composition was Asx 1, Thr 1, Ser 1, Glx 2, Pro 1, Gly 1, Ala 1, Val 1, Ile 1, and Leu 2. Cerulenin 30-39 threonine aldolase GLY1 Saccharomyces cerevisiae S288C 149-154 2666407-5 1989 Tryptic digestion of the [3H] cerulenin-treated enzyme gave a radioactive peptide; its amino acid composition was Asx 1, Thr 1, Ser 1, Glx 2, Pro 1, Gly 1, Ala 1, Val 1, Ile 1, and Leu 2. Cerulenin 30-39 alanine--tRNA ligase Saccharomyces cerevisiae S288C 156-161 2666407-5 1989 Tryptic digestion of the [3H] cerulenin-treated enzyme gave a radioactive peptide; its amino acid composition was Asx 1, Thr 1, Ser 1, Glx 2, Pro 1, Gly 1, Ala 1, Val 1, Ile 1, and Leu 2. Cerulenin 30-39 3-isopropylmalate dehydrogenase Saccharomyces cerevisiae S288C 181-186 3347929-3 1988 As judged by 14C-serotonin release, concentrations of cerulenin required for the half-maximal inhibition of thrombin-induced activation were 5-10 and 70 micrograms/ml in the incubation for 120 min at 37 degrees C for washed platelets and those in platelet rich plasma, respectively. Cerulenin 54-63 coagulation factor II, thrombin Homo sapiens 108-116 3194424-6 1988 Cerulenin, an inhibitor of de novo fatty acid biosynthesis, inhibited the myristoylation and the proteolytic cleavage of the gag-coded polyprotein Pr53gag to p24 but did not affect the processing of gp160. Cerulenin 0-9 protein phosphatase 2 phosphatase activator Homo sapiens 147-151 3194424-6 1988 Cerulenin, an inhibitor of de novo fatty acid biosynthesis, inhibited the myristoylation and the proteolytic cleavage of the gag-coded polyprotein Pr53gag to p24 but did not affect the processing of gp160. Cerulenin 0-9 transmembrane p24 trafficking protein 2 Homo sapiens 158-161 3194424-6 1988 Cerulenin, an inhibitor of de novo fatty acid biosynthesis, inhibited the myristoylation and the proteolytic cleavage of the gag-coded polyprotein Pr53gag to p24 but did not affect the processing of gp160. Cerulenin 0-9 glutamyl aminopeptidase Homo sapiens 199-204 3347929-0 1988 Inhibition by the antilipogenic antibiotic cerulenin of thrombin-induced activation of human platelets. Cerulenin 43-52 coagulation factor II, thrombin Homo sapiens 56-64 3347929-1 1988 Upon incubation with an antibiotic cerulenin, human platelets lost their abilities to aggregate and to release serotonin or ATP in response to various stimuli such as thrombin, ADP, collagen and platelet activating factor. Cerulenin 35-44 coagulation factor II, thrombin Homo sapiens 167-175 3347929-6 1988 When effects of cerulenin on intracellular Ca2+ concentration were examined, mobilization of intracellular Ca2+ by thrombin was significantly depressed in the cerulenin-treated platelets as judged by Fura2, Quin2 or chlortetracycline fluorescence. Cerulenin 16-25 coagulation factor II, thrombin Homo sapiens 115-123 3347929-6 1988 When effects of cerulenin on intracellular Ca2+ concentration were examined, mobilization of intracellular Ca2+ by thrombin was significantly depressed in the cerulenin-treated platelets as judged by Fura2, Quin2 or chlortetracycline fluorescence. Cerulenin 159-168 coagulation factor II, thrombin Homo sapiens 115-123 6229601-0 1983 Membrane perturbation by cerulenin modulates glucosyltransferase secretion and acetate uptake by Streptococcus salivarius. Cerulenin 25-34 SSAL8618_RS07090 Streptococcus salivarius 45-64 3489314-0 1986 Inhibition of cleavage of Moloney murine leukemia virus gag and env coded precursor polyproteins by cerulenin. Cerulenin 100-109 endogenous retrovirus group K member 20 Homo sapiens 64-67 3489314-4 1986 We found that in pulse (15 min-2 hr)-chase (0-4 hr) experiments the cleavage of not only Pr65gag to p30 and other gag coded proteins but Pr80env to gp70 and Pr15(E) as well, was greatly reduced by cerulenin treatment. Cerulenin 197-206 CD59 molecule (CD59 blood group) Homo sapiens 27-32 3489314-4 1986 We found that in pulse (15 min-2 hr)-chase (0-4 hr) experiments the cleavage of not only Pr65gag to p30 and other gag coded proteins but Pr80env to gp70 and Pr15(E) as well, was greatly reduced by cerulenin treatment. Cerulenin 197-206 centromere protein V Homo sapiens 100-103 3489314-5 1986 Further, since the total amount of label in the Pr65gag and Pr80env bands remained about the same or was slightly decreased in 2-hr pulsed, cerulenin-treated cells, this suggests that cerulenin decreases virus production, in part, by inhibiting the cleavage of both precursor gag and env coded polyproteins during virus assembly and budding at the cell membrane. Cerulenin 184-193 endogenous retrovirus group K member 20 Homo sapiens 64-67 3489314-6 1986 We also observed that at longer chase periods (4 hr), the effect of cerulenin could be partially overriden in that minor amounts of cleaved gag and env coded polyproteins were produced and assembled into virion particles. Cerulenin 68-77 endogenous retrovirus group K member 20 Homo sapiens 148-151 6492118-0 1984 Inhibition of secretion of staphylococcal alpha toxin by cerulenin. Cerulenin 57-66 AT695_RS01930 Staphylococcus aureus 48-53 6492118-1 1984 Secretion of alpha toxin by Staphylococcus aureus strain Wood 46 was preferentially inhibited by cerulenin, an antibiotic that stops fatty-acid synthesis by inhibiting beta-keto acyl acyl carrier-protein synthetase. Cerulenin 97-106 AT695_RS01930 Staphylococcus aureus 19-24 6492118-3 1984 Extracellular and membrane-associated alpha toxin was absent in cultures treated with cerulenin, but toxin formation was resumed after either removal of the antibiotic or addition of exogenous fatty acids. Cerulenin 86-95 AT695_RS01930 Staphylococcus aureus 44-49 3019002-3 1986 This effect appears specific for the Pr65gag polyprotein, since the env precursor polyprotein Pr80env was normally synthesized and remained undegraded in cerulenin-treated 3JE-infected cells. Cerulenin 154-163 melanoma antigen Mus musculus 68-71 6229601-1 1983 Cerulenin and dodecanoic acid prevented the synthesis and secretion of glucosyltransferase in non-proliferating cell suspensions of Streptococcus salivarius ATCC 25975 under conditions that also inhibited the incorporation of radioactively labelled acetate into the cell. Cerulenin 0-9 SSAL8618_RS07090 Streptococcus salivarius 71-90 6229601-5 1983 These and other observations strongly suggested that cerulenin inhibited glucosyltransferase secretion and acetate incorporation by perturbing the membrane, rather than by directly inhibiting lipid synthesis. Cerulenin 53-62 SSAL8618_RS07090 Streptococcus salivarius 73-92 33292328-7 2020 Cerulenin was used to block the NF-kappaB cofactor function of TonEBP. Cerulenin 0-9 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 32-41 6756301-0 1982 Secretion of beta-lactamase by Escherichia coli in vivo and in vitro: effect of cerulenin. Cerulenin 80-89 beta-lactamase Escherichia coli 13-27 6756301-1 1982 The effect of cerulenin on the production of beta-lactamase and other periplasmic proteins was studied in Escherichia coli IA199 carrying plasmid pBR322. Cerulenin 14-23 beta-lactamase Escherichia coli 45-59 6756301-2 1982 Cerulenin (10 to 25 microgram/ml) had almost no effect on the growth rate of E. coli but it decreased the amount of beta-lactamase and other periplasmic proteins in shock fluid. Cerulenin 0-9 beta-lactamase Escherichia coli 116-130 33292328-7 2020 Cerulenin was used to block the NF-kappaB cofactor function of TonEBP. Cerulenin 0-9 nuclear factor of activated T cells 5 Mus musculus 63-69 33292328-11 2020 Cerulenin disrupted the assembly of the TonEBP/NF-kappaB/AP-1/p300 complex and suppressed the LPS-induced microglial activation and the neuronal damages in animals. Cerulenin 0-9 nuclear factor of activated T cells 5 Mus musculus 40-46 33292328-11 2020 Cerulenin disrupted the assembly of the TonEBP/NF-kappaB/AP-1/p300 complex and suppressed the LPS-induced microglial activation and the neuronal damages in animals. Cerulenin 0-9 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 47-56 33292328-11 2020 Cerulenin disrupted the assembly of the TonEBP/NF-kappaB/AP-1/p300 complex and suppressed the LPS-induced microglial activation and the neuronal damages in animals. Cerulenin 0-9 jun proto-oncogene Mus musculus 57-61 33292328-11 2020 Cerulenin disrupted the assembly of the TonEBP/NF-kappaB/AP-1/p300 complex and suppressed the LPS-induced microglial activation and the neuronal damages in animals. Cerulenin 0-9 E1A binding protein p300 Mus musculus 62-66 33292328-13 2020 Cerulenin is an effective blocker of the TonEBP actions. Cerulenin 0-9 nuclear factor of activated T cells 5 Mus musculus 41-47 31954918-10 2020 Furthermore, enzyme inhibition assay of FAS2 with cerulenin strengthen the computational outcome with MIC 1.25 mug/mL. Cerulenin 50-59 N terminal fragment of fatty acid synthase alpha subunit similar to S. cerevisiae FAS2 (YPL231W) multifunctional enzyme that catalyzes synthesis of long-chain saturated fatty acids Candida albicans SC5314 40-44 30767875-6 2019 To reveal the interaction between NF-kappaB and NFAT5, cerulenin, which disrupts their interaction, was used. Cerulenin 55-64 nuclear factor kappa B subunit 1 Homo sapiens 34-43 31678479-5 2019 We demonstrate that pharmacologic manipulation of FASN or SCD1 enzymatic activity by non-toxic concentrations of cerulenin or CAY10566 decreases CHIKV genome replication. Cerulenin 113-122 fatty acid synthase Homo sapiens 50-54 31678479-5 2019 We demonstrate that pharmacologic manipulation of FASN or SCD1 enzymatic activity by non-toxic concentrations of cerulenin or CAY10566 decreases CHIKV genome replication. Cerulenin 113-122 stearoyl-CoA desaturase Homo sapiens 58-62 30767875-6 2019 To reveal the interaction between NF-kappaB and NFAT5, cerulenin, which disrupts their interaction, was used. Cerulenin 55-64 nuclear factor of activated T cells 5 Homo sapiens 48-53 30767875-12 2019 Cerulenin repressed the expressions of IL-6, CCL20 and IL-8 in RASFs stimulated by LTF. Cerulenin 0-9 interleukin 6 Homo sapiens 39-43 30767875-12 2019 Cerulenin repressed the expressions of IL-6, CCL20 and IL-8 in RASFs stimulated by LTF. Cerulenin 0-9 C-C motif chemokine ligand 20 Homo sapiens 45-50 30767875-12 2019 Cerulenin repressed the expressions of IL-6, CCL20 and IL-8 in RASFs stimulated by LTF. Cerulenin 0-9 C-X-C motif chemokine ligand 8 Homo sapiens 55-59 30767875-12 2019 Cerulenin repressed the expressions of IL-6, CCL20 and IL-8 in RASFs stimulated by LTF. Cerulenin 0-9 lactotransferrin Homo sapiens 83-86 30779961-5 2019 We treated OVX C57BL/6 mice with cerulenin (a known inhibitor of FAS) for 6 weeks and compared their bone phenotype with vehicle-treated controls. Cerulenin 33-42 fatty acid synthase Mus musculus 65-68 29352103-9 2018 We found that cerulenin pretreatment inhibited t-SNARE acylation and platelet function in a dose- and time-dependent manner whereas palmostatin B had no detectable effect. Cerulenin 14-23 small NF90 (ILF3) associated RNA E Homo sapiens 49-54 29113229-4 2017 Cerulenin was used as a FASN inhibitor. Cerulenin 0-9 fatty acid synthase Homo sapiens 24-28 29113229-8 2017 Inhibition of FASN by cerulenin resulted in a significant decrease in expression of ErbB1, 2 and 4 (P<0.001), whereas there was no evident change in ErbB3. Cerulenin 22-31 fatty acid synthase Homo sapiens 14-18 29113229-8 2017 Inhibition of FASN by cerulenin resulted in a significant decrease in expression of ErbB1, 2 and 4 (P<0.001), whereas there was no evident change in ErbB3. Cerulenin 22-31 epidermal growth factor receptor Homo sapiens 84-98